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SMALL MOLECULES AS PROBES FOR CELL DIVISION AND 
INTRACELLULAR TRANSPORT 
Ulf Peters, Ph.D. 
The Rockefeller University 2008 
 
Cell-permeable small molecules that can act on their targets on fast time scales 
are powerful probes of cell division mechanisms and intracellular transport 
processes. Phenotype-based screens with chemical libraries have been used to 
identify such inhibitors. However, probes for most proteins are still not available, 
and the requirements on compound collections to yield such probes are not well 
understood. Here I present two approaches to find and use such probes.  
First, in an attempt to find probes for cell division, I have shown that a small 
collection of 100 diaminopyrimidines yielded a range of cell division phenotypes, 
including changes in spindle geometry, chromosome positioning and mitotic 
index. Monopolar mitotic spindles were induced by 4 inhibitors including one that 
targets Polo-like kinases, evolutionarily conserved serine/threonine kinases. 
Using chemical inhibitors and high-resolution live-cell microscopy, I found that 
Polo-like kinase activity is needed for the assembly and maintenance of bipolar 
mitotic spindles. Inhibition of Polo-like kinase destabilized kinetochore 
microtubules while stabilizing other spindle microtubules, leading to monopolar 
spindles.  
 
Second, I used pigment organelles in Xenopus melanophore cells, a specialized 
intracellular transport system for which the motor proteins driving movement, and 
primary signals regulating movement, are known, to identify inhibitors of 
intracellular transport. Screening of an unbiased commercial library yielded a 
compound, 37P11, that could be characterized as possible inhibitor of a yet 
unknown element in the regulation of organelle movement. From a collection of 
diaminopyrimidines, one compound, DAP-29, was identified that potentially 
targets cytoplasmic dynein, an essential motor protein in many transport 
processes. Both compounds showed activity in assays in a variety of other 
intracellular transport systems, highlighting their potential use as biological 
probes. 
 My findings indicate that development of new screening systems and further 
testing of compounds based on „privileged scaffolds‟, such as 
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1.1. Small Molecule Inhibitors in Cell Biology 
In cell biology, the idea that small molecules can be used to perturb the function 
of specific proteins has gained more traction in the last few years. This is an 
expected development, considering that many cellular functions are carried out 
by small molecules (nucleotides, steroid hormones, neurotransmitters) and that 
the use of small molecules has been a cornerstone of pharmacology. The main 
advantages of small molecules are: their rapid action, which might be just 
diffusion limited and allows a „conditional‟ introduction at precise points in time, 
their potential reversibility, their tunable effects using different concentrations, the 
potential to easily use several inhibitors at once, and, in case of inhibitors of 
enzymatic activity, a modulation of activity without removal of the protein itself. 
Despite these clear advantages, identifying small molecules that bind specifically 
to a single protein remains a challenge, especially given that binding/active sites 
in homologous proteins can be very similar. In addition, small changes in 
chemical structure can affect the binding properties of small molecules greatly. 
This sensitivity usually prevents simple correlations or predictions to be made for 
suitable small molecules for a particular binding site, and often requires treatment 
of each small molecule as a unique case. 
In cell biology the availability of genomic information has enabled more 
generalizable, but still specific, approaches with the use of genetic techniques 









insights into cell biology have come from forward genetic approaches such as 
screening a library of mutants for phenotypic changes, coupled with the 
subsequent identification of the relevant protein, or reverse genetic approaches, 
such as protein knock-outs or knockdowns to study the resulting phenotype. 
However, these methods have drawbacks as well. Lethal knock-outs can be 
difficult to study, genetic mutants are typically not conditional and cannot be 
turned on or off at will, and knock-out/-down phenotypes can often be masked by 
functional compensation by a related gene. In addition, processes that can occur 
on a second or minute time scale such as intracellular transport can be difficult to 
study given that genetic techniques often require much more time (Figure 1). 
While small molecules cannot replace genetic approaches in cell biology they 
can complement them by providing a general means of rapidly and conditionally 
inactivating proteins, as has been shown in numerous examples (see below). 
Since the number of small molecule inhibitors used in cell biology is still low, 
identifying new ones, as well as learning more efficient ways to find them, will 




Figure 2: Overview of Mitosis 
(A) Chromosomes are replicated before mitosis and sister chromosomes are held together. (B) 
After chromosome condensation and nuclear envelop breakdown the mitotic spindle forms and 
attaches to the chromosomes. (C) Chromosomes move to the center of the spindle and become 
aligned in metaphase. (D) Sister chromosomes separate at anaphase and move in opposite 
directions. (E) The cell divides as the cleavage furrow forms in cytokinesis between the separated 
chromosomes. (F) Two daughter cells with the exact copy of the genetic material at the end of 
cell division. 
 
1.1.1. Small Molecule Inhibitors in Cell Division 
During cell division, the genetic content of a cell is equally partitioned between 
two daughter cells (Figure 2A-F). Errors in this process are linked to 
developmental defects, and cell division gone awry is a hallmark of human 
diseases, such as cancer1. Cell division is a dynamic process that can be 
completed within an hour, a small fraction of a typical cell cycle2. Key processes, 
such as chromosome movements, occur at 1-6 microns/min, with individual 
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events, such as changes in directions of movement, taking seconds3. Therefore, 
error-free cell division requires a regulation of dynamic processes at specific 
cellular sites and at precise times. The molecular basis for this regulation is 
poorly understood.  
Cell-permeable small molecules can target proteins on fast time scales, allowing 
inhibition or activation of function in live cells within minutes. This feature of small 
molecule inhibitors can be particularly useful in examining cell division dynamics, 
considering that all of cell division takes place in approximately 1 hour4. The 
mitotic spindle is a multi-component cellular machine that carries out DNA 
segregation during cell division. Several proteins required for mitotic spindle 
function represent potential targets for chemical inhibition. Microtubules, 
polymers of the cytoskeletal protein tubulin, provide a mechanical framework for 
mitotic spindle function3. The functions of tubulin in mitotic spindle assembly, 
chromosome movement, regulation of cell cycle progression, orientation of the 
cell division axis, and positioning of the cell cleavage plane have been revealed 
using compounds that directly target this protein4. Tubulin poisons are also 
effective chemotherapy agents used to treat diseases such as cancer, as 
inhibition of tubulin function blocks cell division and tumor growth5. 
A classic small molecule agent is the natural product colchicine (Figure 3). While 
it was known that colchicine induces mitotic arrest2, the compound‟s mode of 
action was unclear. Shinya Inoue used it to treat cells in metaphase and 
observed a disappearance of the mitotic spindle fibers. The fibers could be 




Figure 3: Chemical Structures of Small Molecules That Act on Microtubules 
 
synthesis, implying that the spindle fibers are polymers made up from a pool of 
readily available monomers6,7. In addition, upon treatment with a low 
concentration of colchicine, chromosomes could be seen moving towards the 
pole, indicating that depolymerization of the filament might be coupled to 
chromosome movement8. A breakthrough in understanding the mechanism of 
colchicine came with target identification studies using a tritium label, which 
showed a reversible association with intracellular fibers called microtubules and 
led to the identification of the protein tubulin as the monomeric subunit9.  
Other microtubule depolymerizers like nocodazole have also found wide use in 
cell biology, for example to study transport processes or chromosome 
attachment in the absence of polymerized microtubules without affecting the 
monomeric protein. Interestingly, microtubule-stabilizing small molecules like 
taxol proved useful as well (Figure 3). Taxol stabilization of microtubules greatly 
affects their inherent dynamic properties. As a result, microtubules can still attach 
to kinetochores on chromosomes but are unable to create the necessary pulling 
forces to create tension across a kinetochore pair, assuming an attachment to 
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opposing poles in the mitotic spindle. Using this perturbation it was possible to 
show that a cell can recognize the absence of chromosome attachment 
(nocodazole treatment), but not necessarily the absence of tension (taxol 
treatment)10-12.   
Protein phosphorylation is a reversible modification essential in most signaling 
pathways. Kinases that are responsible for this modification are crucial 
components in cell division as well. Small molecule kinase inhibitors have proven 
to be useful probes. One such example is hesperadine, used to inhibit Aurora 
kinases, a class of proteins essential for cell division. Lampson et al. used this 
inhibitor to understand the role of Aurora kinases in the correction of 
chromosome attachment errors13.  It was found that addition of hesperadine 
blocked error correction by stabilizing incorrect attachments, and after 
reactivation of the kinase by removal of the compound, the incorrect attachments 
became destabilized, clearly demonstrating the role of Aurora kinase in this 
process. The use of the small molecule combined with live-microscopy allowed 
them to look at a specific time in cell division, which was necessary since Aurora 
kinases have several roles throughout mitosis. In addition, the enzyme could be 
switched on and off with a high temporal control due to the reversibility of the 
small molecule. 
At the end of cell division, following transport of chromosomes to the opposing 
poles, the cell physically divides into two daughter cells, in a process termed 
cytokinesis. Small molecules have helped to elucidate key aspects of this 




Figure 4: The Contractile Ring in Cytokinesis 
(A) A ring of actin filaments and myosin II forms at the plasma membrane and contracts to divide 
the cell in half. (B) Chemical structure of cytochalasin B, a small molecule that targets actin. (C) 
Chemical structure of blebbistatin, a compound that targets myosin II. 
existed around the cleavage furrow, termed microfilaments, but its identity was 
unclear (Figure 4A)14. Treatment with the small molecule cytochalasin led to its 
disruption and prevented furrow contraction in cytokinesis (Figure 4B). 
Interestingly, cytochalasin also blocked other forms of cellular or intracellular 
processes, such as cell motility and membrane ruffling15,16. Microfilaments were 
shown to be present in all of these systems. The use of colchicine demonstrated 
that such microfilaments seem to be unrelated to microtubules, leading to the 
conclusion that microfilaments were another crucial player in force generation in 
cells16. Treatment of purified actin fibers from muscle cells with cytochalasin led 
to a decreased viscosity, which suggested two conclusions: first, that the 
molecular target of cytochalasin is actin, and second, that the processes inhibited 
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by cytochalasin rely on actin for force generation. Therefore, the observed 
microfilaments contain actin as critical component. The molecular motor protein 
that works on the actin filaments in cytokinesis to allow contraction is myosin II. 
Recently a small molecule inhibitor of this motor protein, named blebbistatin, has 
been identified using a high-throughput screen (Figure 4C)17. Addition of 
blebbistatin to cells leads to a block in cytokinesis leaving components of the 
cleavage furrow in the correct position, but unable to carry out contraction. With 
cytokinesis arrested at this point, other small molecules could then be used to 
investigate the molecular requirements for furrow positioning without affecting 
preceding processes. For instance, it has been shown that signals from Aurora 
kinases as well as Rho kinases are necessary to localize myosin II to the 
cleavage furrow17. 
While small molecules have contributed crucial insights into cell division, the 
regulation of this highly dynamic process is still not well understood. 
Development of specific inhibitors for each protein involved, a continually growing 
list, would be ideal to answer the many outstanding questions. The identification 
of new small molecule inhibitors in cell division may also help to verify protein 
targets in diseases such as cancer, as the example of taxol and tubulin shows. 
1.1.2. Small Molecule Inhibitors in Other Areas of Cell Biology 
As the examples from cell division demonstrate, small molecules are valuable 
tools to study biological processes, with the potential to impact drug discovery. 
Since many processes in cell biology occur on a fast time scale, the use of small 
molecules has extended into areas as diverse as cell motility and migration18, 
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aggresome formation19, membrane transport20, and nuclear export21. It should 
also be noted that although small molecules may not be the focus of a study they 
can play supporting roles such as inhibiting protein synthesis at precise points in 
time (cycloheximide), preventing degradation of proteins by certain pathways 
such as proteasome inhibition (MG132), or overriding DNA damage checkpoints 
(caffeine). The following examples demonstrate the versatility of small molecules 
and their applications. 
Actin filaments are not only necessary during cytokinesis, but they are also 
essential as a cytoskeletal component in cell motility and migration. Therefore, 
the identification of actin as a target of cytochalasins, as described above, was 
important for this field as well. In a recent study, several small molecules have 
been used to better understand the interplay between actin, myosins and 
upstream signaling proteins in cell motility22. Using blebbistatin to disrupt myosin 
II, a kinase inhibitor that implicated Rho-kinase as responsible upstream signal, 
and calyculin A (Figure 5), a known phosphatase inhibitor, the authors were able 
to learn more about how a radially symmetric cell can initiate polarized cell 
motility in a certain direction.  
Another area where small molecules have helped to gain a deeper 
understanding is vesicle secretion. Brefeldin A (BFA), a fungal metabolite, has 
played a crucial role (Figure 5). Treatment with BFA leads to the disassembly of 
the Golgi complex, a ribbon of stacked, flattened membrane cisternae and 
tubular extensions that is located near the microtubule organizing center. The 




Figure 5: Chemical Structures of Small Molecule Probes for Different Areas of Cell Biology 
Chemical structures of several natural products that have been used as small molecule inhibitors. 
Shown are the phosphatase inhibitor calyculin A, brefeldin A – a blocker of guanine nucleotide 
exchange in vesicle trafficking, and cyclopamine – an inhibitor of Smoothened. 
 
endoplasmic reticulum (ER) to other organelles and is the center of a complex 
intracellular trafficking of lipids and proteins. Disassembly of the Golgi by BFA 
leads to its redistribution into other membrane compartments such as the ER. 
The resulting block of the secretion pathway allowed researchers to study 
dynamic processes such as retrograde transport within the membrane 
compartments23. The molecular target of BFA was also identified as a nucleotide 
exchange factor for small G-proteins involved in ADP-ribosylation, which help to 
assemble the „coats‟ for vesicle trafficking. Interestingly, more recent studies 
including structural data have shown that BFA acts non-competitively by locking 
the ADP-ribosylation factor and its corresponding GDP-exchange factor into an 
inactive conformation of the complex thereby blocking nucleotide exchange and 
activation24.  
Small molecule inhibitors have proven valuable in studying developmental 
processes as well, as the example of the natural product cyclopamine shows 
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(Figure 5). This compound causes cyclopia in sheep25 which resembled 
phenotypes seen of mutations in the sonic hedgehog gene (Shh), an important 
player in signal transduction pathways involved in patterning in many tissues26. 
The target of cyclopamine was identified as Smoothened (Smo), a 
transmembrane protein, that acts as an activator in the hedgehog pathway27. 
Using this inhibitor the role of Smo in the signaling pathway and its interaction 
partners could be better understood. Since the hedgehog pathway is involved in 
cancer as well, understanding the role of cyclopamine also opened a window for 
potential therapeutic intervention in this direction28. 
1.1.3. Alternative Strategies Using Small Molecules 
In the examples described those far, small molecules have been used as direct 
effectors of native proteins. However, small molecules can also be utilized in 
more indirect ways to widen their applicability while still taking advantage of the 
temporal control they can provide.  
The bump-hole approach, brought to prominence by the Shokat laboratory, 
combines the use of small molecules with protein engineering and has been 
especially successful with kinases. The method relies on the engineering of a 
functionally silent, but structurally significant, mutation in the ATP-binding pocket 
of the target kinase. In most cases this is achieved by a replacement of a 
conserved bulky residue with a smaller amino acid like glycine or alanine29. This 
generates a bigger pocket, the so called „hole‟, ideally without greatly affecting 
the enzymatic activity. A non-specific small molecule inhibitor of the wild-type 




Figure 6: Schematic Overview over the Bump-hole Approach in Kinases 
Kinase specific inhibition can be achieved by a combination of protein and small molecule 
engineering. Wild-type and mutant kinase both have enzymatic activity relying on binding to ATP. 
The unmodified inhibitor is not selective for either form of the kinase or for highly conserved 
binding active sites of other kinases. The „bumped‟ inhibitor can only bind to the mutated kinase, 
providing selectivity over wild-type kinase and kinases with related active sites. + indicates 
binding to kinase.  
complement the mutation introduced into the active site, resulting in a „bump‟ on 
the inhibitor. Due to steric clashes, the „bumped‟ inhibitor should be unable to 
bind the wild-type active site, while being selective for the engineered protein 
(Figure 6). In the last step, the wild-type kinase needs to be replaced by the 
engineered one. This approach allows one to engineer specificity into inhibitors 
of conserved proteins like kinases and provide a means to specifically inhibit any 
protein of choice, given enough structural information and a suitable small 
molecule starting point. However, the replacement of the wild-type protein is not 




Figure 7: Structures of the Common Dimerizers FK-506 and Rapamycin 
can greatly affect enzymatic activity. The bump-hole approach has been 
successful in a number of examples such as determining the role of polo-like 
kinase (Plk) in cytokinesis30, helping to understand the role of myosin Vb in 
membrane trafficking31, and  helping to identify substrates of specific kinases, 
e.g. cyclin dependent kinase 132. 
Small molecules that function as dimerizers by mediating protein-protein 
interaction have proven useful as well. One classic example is the natural 
product FK506, which can induce the heterodimerization of the FK506-binding 
protein (FKBP) and a portion of the FKBP12-rapamycin-associated protein 
(FRAP)33 (Figure 7). By using a dimer of FK506, called FK1012, a 
homodimerization of FKBP domains can be induced. If the FKBP-domains are 
attached to a protein of interest, oligomerization of this protein can be achieved in 
a FK1012 dependent manner.  Using this inducible system, the Schreiber 
laboratory was able to oligomerize the Fas-receptor which is important in 
apoptotic signaling, and show that the dimerization of the receptor was sufficient 
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to induce apoptosis34. The idea of induced dimerization or oligomerization 
mediated by introduced protein domains is not limited to the studies of receptors. 
The Crews laboratory developed proteolysis targeting chimeric molecules 
(PROTACs) that consist of a ligand, for instance on FKBP ligand, and a short 
peptide sequence that can be recognized by ubiquitin ligase35. If the protein of 
interest is fused to a FKBP domain, the PROTAC can then bind to this fusion and 
recruit the ubiquitin ligase, leading to the ubiquitination of the target protein which 
marks it for degradation by the proteasome. Therefore, the PROTAC allows for 
induced protein degradation. Small molecule induced dimerization can be used in 
yet another way as a switch to activate or inhibit protein function, as the Muir 
laboratory has shown. Combining protein splicing, an editing process that 
removes a defined internal domain from a protein (intein), and fuses the flanking 
external domains (exteins), with induced dimerization allows for the rapid 
formation of a functional protein upon addition of the small molecule, resulting in 
conditional protein splicing36. Using rapamycin and its binding partners FKBP and 
FRAP in this system, formation of functional proteins could be induced in whole 
organisms37 (Figure 7). 
While all of the described alternative approaches for the use of small molecules 
hold promise, considering that one small molecule could work on a range of 
different proteins, they rely on protein engineering, which may not always be 
successful. Nevertheless, these techniques nicely complement the „classic‟ small 
molecule approach and can be viable alternatives. 
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1.2. Finding Small Molecule Inhibitors 
To find suitable small molecule probes, several key questions need to be 
addressed. What process/enzyme needs to be perturbed, and are there assays 
available to read out a perturbation? What part of chemical space should be 
searched for the small molecule? Most of the examples described here so far 
have been natural products that showed biological activity and therefore were 
analyzed further for their molecular target, their specificity, and their mode of 
action. While the approach to use „nature‟ to design, synthesize, and screen 
small molecules has been very fruitful in the past, the advent of large scale 
chemical syntheses, especially combinatorial approaches and the wider 
availability of recombinant proteins, have led people to focus on generating and 
screening chemical libraries in order to find new small molecule probes and 
expand the scope of inhibitable proteins.  
1.2.1. Available Compound Collection 
Collections of natural products and extracts that take advantage of the natural 
biodiversity remain an important part in the discovery process of small molecule 
inhibitors. However, they are often difficult to isolate or synthesize in a large 
enough quantity, making target identification and biological application difficult. 
Large libraries of compounds can and have been generated using combinatorial 
chemistry38. They might consist of compounds from a number of easily 
accessible scaffolds, often heterocycles that are chemically elaborated to 
produce compounds that contain sterically and/or electronically diverse 
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appendages at various positions. To expand the number of available scaffolds 
and achieve greater structural variety, diversity-oriented chemistry can be used 
as an alternative approach39. With the screening and testing of compounds from 
many different scaffolds against a range of targets, it became clear that a subset 
of the scaffolds are capable of binding to a variety of protein targets with high 
affinity40. These particular structural motifs are often referred to as „privileged 
scaffolds‟40. Libraries based on a „privileged scaffold‟ have been successful in a 
number of examples, such as for 2,6,9-trisubstituted purines leading to inhibitors 
of kinases41,42, and may hold promise as a general approach to identify small 
molecule probes. 
With a large number of screens having been carried out, especially in industrial 
drug development, it has become clear that bioactive small molecules often 
follow certain rules regarding their chemical and physical properties. The 
„Lipinski‟ rule of five states that an orally active drug should have: 1) no more 
than 5 hydrogen bond donors, 2) no more than 10 hydrogen bond acceptors, 3) a 
molecular weight under 500 g/mol, and 4) a partition coefficient log P of less than 
543. Although this rule refers to drug candidates and is not exclusive, it can 
provide a framework for a higher success rate, and is often followed for 
commercially available libraries. Compiling the results from many screens has 
also enabled access to compound collections consisting of previously identified 
bioactive compounds which may have activities in other areas as well. 
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1.2.2. In Vitro Screening Approaches Using Pure Proteins 
If the protein target of interest is known and can be purified in sufficient quantity, 
screening for small molecules that modulate its activity is often carried out in an 
in vitro system. This approach has been especially successful with enzymes and 
receptors for two reasons. First, most of them have evolved to interact strongly 
and specifically with small molecules such a nucleotides, lipids, and steroid 
hormones, and therefore contain a suitable small molecule binding pocket. 
Second, readouts for a range of enzymatic activities and binding assays for small 
molecules, often based on fluorescent species, are available to allow for high-
throughput screening. 
Using pure proteins/peptides to find inhibitors of protein-protein interactions is 
possible as well, but due to the problems associated with this inhibition, such as 
the large binding interfaces and high number of protein-protein contacts, finding 
small molecule probes has not been as successful. An alternative to the classic 
screening of small molecule libraries in this regard are fragment-based discovery 
approaches44-46.  They rely on using fragments, small organic molecules typically 
less than 200 Da, to screen for binding to a protein target. Active fragments, 
which usually have binding constants in the millimolar range, are then linked to 
generate larger sized compounds, which then can be screened for improved 
function. Because of the relatively low affinity of fragments, their discovery and 
characterization can be a challenge. Techniques such as structure-activity 
relationship (SAR) by NMR45, which uses NMR as a screening tool but requires a 
solved protein structure, or tethering46, which uses disulfide bonds to tether 
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fragments close to the protein site of interest, have been used to overcome these 
problems and have helped find inhibitors of protein-protein interactions47,48. 
Disrupting protein-protein interaction by targeting inhibitable allosteric sites away 
from the protein-protein interface is another viable alternative49-51. 
While pure proteins are required in these in vitro screens, a major advantage is 
that the target protein of the small molecule is known from the outset. 
Optimization by SAR, especially for potency, can be simply carried out in the 
established screening system. What is harder to address is the question of 
whether the small molecule probe is active in a biological system. Steps like 
adding  high amounts of proteins like casein, to minimize non-specific protein 
binding by compounds, working in the presence of a low concentration of 
detergent to avoid inhibition by compound aggregation52, or suitable library 
design to make bioavailability more likely, can help to increase the chances of 
the hit compound working in vivo, but these methods are not guarantees for 
success. In addition, the question of compound selectivity needs to be addressed 
as well, which holds true for all small molecule inhibitors.  
1.2.3. Phenotype-based Screening Approaches 
The alternative to in vitro screening for a known protein activity or binding 
interaction is to screen in vivo for a desired phenotype. This approach is related 
to classic forward genetic screening where instead of screening a library of 
mutants, a library of small molecules is used to affect a process of interest53. 
Compared to screening with pure proteins, it has two major advantages. First, 
the actual target protein does not need to be isolated or even known, and a direct 
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in vitro activity read-out assay is not necessary either. This allows insight into 
processes where not all the molecular players have been identified and offers a 
larger window of opportunity to find small molecules in. Second, by affecting the 
process in vivo, the hit compounds already show activity in a biological system 
giving them a higher chance to become useful biological probes.  
Identification of the relevant protein target is still necessary to fully understand 
the mode of action of small molecule hits from phenotypic screens. This can 
often be a rate-limiting factor, but several target identification techniques are 
available. One of the classic approaches uses the small molecule or one of its 
analogues as bait to trap the protein. If the small molecule analog contains a tag, 
such as biotin, a fluorescent marker or a radioactive isotope, a covalent 
attachment of the compound to the protein, for instance by chemical or UV-
crosslinking, can then be used to identify the protein by the introduced tag. The 
small molecule – protein interaction can also be used in affinity chromatography-
based approaches, where the small molecule is immobilized via a linker to a solid 
support which is then used to enrich for its protein target. While covalent 
interaction is not necessary for affinity chromatography, the binding interaction 
needs to be sufficiently strong to achieve separation, often requiring affinities in 
the low micromolar or better range. While chemical derivatisation is not possible 
in all cases without significant loss of affinity, alternative strategies for target 
identification are available53. If the observed phenotype is fairly well understood, 
a candidate-based approach can be taken that tests for inhibition of likely target 
proteins. Data available from genome wide RNAi-based phenotypic screens or 
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from classic genetic screens can greatly aid in this process as more and more 
phenotypes are being described. Comparisons with already reported protein 
targets of chemically similar compounds can prove useful as well. In addition, 
designing suitable secondary screens to eliminate compounds with undesired 
modes of action and focusing on more well understood phenotypes should be 
helpful. If the screening system is amenable to large scale genetic techniques a 
suppressor screen of the phenotype induced by the small molecule can be 
carried out. This approach has been used for instance in the nematode C. 
elegans to help identify the protein target of the small molecule nemadipine A. All 
genetic mutants that suppressed the small molecule phenotype were linked to 
one specific calcium channel, and given this finding the authors were then able to 
show that nemadipine A is an antagonist of this channel54.     
As in the case of in vitro screens, the selectivity of the small molecules also 
needs to be addressed, keeping in mind that the observed phenotype may result 
from targeting several proteins, which may in turn also make non-chemical target 
identification approaches more difficult. 
 Of the biological systems amenable to high-throughput phenotypic screening, 
cell culture cells are the most common. The screen usually consists of the 
following steps. First, cells are plated into multi-well plates and incubated with the 
small molecules for an appropriate amount of time. Then the proteins or features 
of interest are made visible, most often fluorescently for instance by 
immunofluorescence using antibodies or tagging with a fluorescent protein, such 
as GFP. Depending on the desired read-out, either a plate reader or an 
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automated microscope can be used to acquire the data. Collecting microscopic 
images often provides additional information such as cellular localization or cell 
shape, and allows the detection of unexpected phenotypic changes more readily, 
but may require more refined analysis techniques. In addition, genetic techniques 
like RNAi, which is available for many cell types, can be used to complement 
phenotypic screening in tissue culture cells. 
Besides the already mentioned example of blebbistatin17 as an inhibitor or 
myosin II, the small molecule monastrol55 was found in a phenotypic cell-based 
screen. Using phosphorylation of nucleolin as read-out for mitosis, compounds 
were selected which caused an increase in mitotic cells (Figure 8A). After a 
secondary screen that eliminated molecules that had an obvious effect on 
microtubules in vitro, which would lead to a mitotic arrest, the cellular phenotype 
of the remaining compounds was analyzed by immunofluorescence. Monastrol 
gave monopolar mitotic spindles, structures with only one pole with the 
chromosomes located radially around it (Figure 8B,C). Guided by the specific 
phenotype observed, the target of this small molecule could be identified as the 
mitotic kinesin Eg5, which is necessary for pole separation. Since its discovery, 
monastrol has been widely used in studies to understand the function of Eg556-58, 
as well as general tool in cell division, for instance to induce a mitotic arrest, to 
accumulate chromosome attachment errors13, or to better understand the 




Figure 8: Monastrol, an Eg5 Inhibitor Discovered in a Cell-Based Screen 
(A) Chemical structure of monastrol, a dihydropyrimidine. (B) Monopolar mitotic spindle are 
observed after monastrol treatment of BS-C-1 cells. Chromatin is shown in blue and -tubulin in 
green. (C) Normal bipolar mitotic spindle as in cells treated with carrier (DMSO). Scale bars, 5 




While cell-based phenotypic screens still are more common, screening for 
phenotypes in whole organisms has proven successful as well. The studies at 
this point have traditionally used small organisms that are genetically tractable. 
One example is the aforementioned identification of nemadipine A as an 
antagonist of a calcium channel in the nematode C. elegans54. Another 
commonly used model organism is the zebrafish Danio rerio, where molecules 
that affect development60, angiogenesis61 or signaling62 have been identified.  
While whole organism screens can easily address questions such as tissue 
specificity, cell-cell interactions in a their normal physiological context, and 
developmental processes, the throughput of the screens is usually lower than in 
cell culture, and phenotypes might be even harder to interpret than in single cells.     
 More and more cell lines and model organisms are becoming available. At the 
same time, improvements in imaging reagents and imaging technology are being 
23 
 
reached. Thus, phenotypic screening will continue to play important roles in small 
molecule discovery.  
1.2.4. Inhibitor Specificity 
While finding small molecule inhibitors can be approached in several different 
ways, one key question that needs to be addressed is their specificity for the 
intended protein target. Given the fact that small molecule binding sites are often 
highly conserved between members of a protein family, or even unrelated 
proteins, it is not unexpected that compounds can often act on multiple targets. 
The identification of the relevant off-targets is therefore crucial to be able to 
correctly correlate effects of the compound with inhibition of the desired protein.  
One of the best studied examples addressing specificity of small molecules are 
inhibitors of kinases. Small molecules have been instrumental in understanding 
the functions of many kinases. A significant challenge to identifying specific, or 
selective, small molecule inhibitors is the highly conserved ATP-binding site 
contained within the ~500 kinases in humans. To assess the specificity of a 
kinase inhibitor several techniques can be used. Typically the compound is 
tested in an in vitro activity assay against a panel of available kinases to 
determine and compare potency among the panel members. Although this data 
gives an indication of specificity, it requires the isolation or recombinant 
expression of a large number of kinases. Furthermore, since the assay is carried 
out in vitro, factors that affect kinase activity such as native complexes of the 
kinase, local concentration, relevant physiological substrates, or alternative 
splice-forms of the kinase cannot be easily addressed63. Affinity chromatography 
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has also been used to identify kinase inhibitor targets and off-targets, employing 
an immobilized compound and subsequent analysis by mass spectrometry64. 
More recently binding assays to the ATP-site of kinases have been used to look 
at specificity, as well65,66. Expressed kinases are allowed to bind to an 
immobilized non-specific inhibitor.  Free test compound is added, which may or 
may not affect this binding interaction, thereby reporting on specificity without the 
need to immobilize the compound of interest. An extension of this idea is the use 
of „kinobeads‟, which are loaded with several non-specific inhibitors, and can be 
used to pull out a large number of kinases from cell extracts in the presence of 
absence of test compound67. Subsequent mass spectrometric identification of 
bound proteins can then give information on disrupted interactions and 
specificity. By employing this array of techniques, it has been found that all 
kinase inhibitors affect a varying number of off-target proteins.  
The described in vitro assays for kinases can indicate whether the compound of 
interest is a promiscuous inhibitor or if it is selective. A correlation between 
potency and selectivity has also been found63. However, the assays usually 
cover only a subset of potential target proteins under in vitro conditions, making it 
necessary to address the specificity of compounds in the relevant biological 
context by additional means. The most valuable tool in this regard is a 
structurally unrelated chemical compound that targets the same protein13,63,68. 
This independent positive control is predicted to have different off-targets due to 
a different chemical structure. Observation of the same dose-dependent, in vivo 
phenotype in both cases would then help to confirm the correlation between a 
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small molecule, its relevant protein target, and the observed effects. 
Furthermore, measures such as working at the lowest inhibitor concentration 
possible can help to limit problems arising from off-target effects63. 
While the aforementioned techniques help to choose the most selective inhibitors 
available and minimize the potential risk of off-target effects, finding compounds 
that are highly specific for one kinase remains difficult. Approaches using protein 
and inhibitor engineering can get closer to this goal. One of them is the „bump-
hole approach‟ described earlier that allows the use of a bulky inhibitor that most 
likely does not target any other kinase. Another approach is the use of a reactive 
cystein close to the active site as one „selectivity filter‟. By equipping an inhibitor 
with an electrophilic group such as a haloketone that is properly positioned to 
react with the cystein, a highly potent irreversible inhibitor can be obtained69. 
Using this particular inhibitor as reactive probe to determine specificity, it was 
shown that only 2 kinases are covalently targeted in human cell lysate69. 
As the example of the kinase field illustrates, inhibitor specificity still remains a 
major factor to be considered when using small molecules. In vitro assays can 
help to improve and develop more specific inhibitors, but cannot rule out or 
address all off-target activities. Therefore, in an in vivo system, the use of 
inhibitors with different chemical structures, careful target validation, and 
comparison with phenotypes obtained from other experimental approaches are 
necessary to reliably correlate inhibition of the intended protein target with the 
biological effects observed. 
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There are many ways to find small molecule inhibitors, each associated with their 
advantages and disadvantages. Choosing the appropriate way to proceed mainly 
depends on the biological problem at hand and a careful choice should increase 
the chances of identifying a specific, biologically active probe. 
1.3. Outlook 
Small molecules as biological tools have helped to better understand dynamic 
processes in cell biology. But many questions still remain unanswered, mainly 
due to the lack of suitable small molecules. The work I present here addresses 
several aspects of this problem. First, I developed and utilized screens for small 
molecule inhibitors, in one case a phenotypic cell-based screen for cell division 
and in the other case a cell-based phenotypic screen for intracellular transport. 
Both screens gave promising hit compounds. Second, I designed compounds 
based on a „privileged scaffold‟ to be used in the screens. These compounds 
were compared to compounds from commercial libraries to better understand the 
compound collection requirements to yield hits. Third, using small molecule 
inhibitors of Polo-like kinase 1 I was able to further elucidate its role during cell 
division. I hope that my work can serve as a step forward towards the goal of 
finding potent and selective effectors of functionally important proteins. 
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2. Probing Cell-division Phenotype Space and Polo-like 
Kinase Function Using Small Molecules 
2.1. Introduction 
As described earlier, small molecules have played crucial roles in understanding 
the intricate details of the highly dynamic processes in cell division, due to the 
exquisite spatio-temporal control they can deliver. However, the control and 
regulation of these processes is still poorly understood. In addition, while a large 
number of proteins required for cell division have been reported, and their knock-
down phenotypes have been described70,71, small molecule inhibitors for most of 
these proteins are not available. Further, the consequences of inhibiting their 
activities without directly reducing protein levels, a predominant mode of action 
for chemotherapy agents, are not known68,72. It is likely that small molecules that 
inhibit these proteins would be powerful tools to analyze the function of their 
target proteins during cell division, and would help to evaluate them as drug 
targets4. 
To identify small molecule inhibitors of cell division proteins, activity-based 
screens or cellular phenotype-based assays can be used. While both 
approaches have advantages and limitations as described previously, cellular 
phenotype-based screens have the potential to identify compounds that are 
active in cells and can lead to the discovery of new mechanisms73. An 
outstanding question is how diverse a collection of compounds must be screened 
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to identify inhibitors that target different proteins, using either method. Advances 
in chemical synthesis technologies are allowing large libraries to be generated74. 
Compound collections can be synthesized that either densely explore regions of 
chemical space occupied by a known bio-active compound, or that occupy other, 
yet untested, regions of this infinite multi-parameter space75. How effectively 
these different compound collections can span cell division phenotype space 
remains unclear. 
2.2. The Screen 
2.2.1. Compound Design and Synthesis 
As a first step in addressing questions related to the extent and type of chemical 
diversity needed to span cell division phenotype space, I, together with Joseph 
Cherian, designed a chemical library based on diaminopyrimidines (hereafter, 
DAPs) (Figure 9A). DAPs represent a class of compounds that may be 
considered as a „privileged scaffold‟40 as they are known to target different 
proteins, including reverse transcriptase76, proton pumps77 and kinases78. A 
range of amine substituents, such as alkyl, cycloalkyl, aromatic and 
heteroaromatics was commercially available and could be readily incorporated at 
the 2- and 4-position of the core pyrimidine to vary structure, polarity and 
hydrogen-bonding capacity. Of the large number of such DAPs, focus was put on 
a representative set of 100 compounds. Symmetric substitutions on the 2- and 4-
position (R2 = R3) were avoided to achieve maximum diversity of functional 
groups within a small compound collection. The use of two readily available 




Figure 9: The Diaminopyrimidine Collection Maps into Chemical Space Occupied by 
Known Bioactive Molecules 
(A) 100 compounds based on the diaminopyrimidine scaffold were synthesized. (B) Comparison 
of the chemical descriptor space occupied by a collection of known drugs and bioactive 
molecules, called the Prestwick collection, and the synthesized diaminopyrimidines. Three 
principal components covering over 97% of the variance in a 10-dimensional parameter space 
are shown. 
The specifics of the compound collection are provided in the appendix (Figure 
36A-D). Based on analyses of published work, 6 of the 99 compounds designed 
had been previously reported, but their cell division phenotypes were not known. 
The chemical space occupied by the selected diaminopyrimidines was compared 
to that spanned by a commercially available compound collection, the Prestwick 
collection, which is selected for structural diversity, known safety and 
bioavailability in humans and over 85% of the compounds are marketed drugs 
(www.prestwickchemical.com). The 100 DAPs and ~880 Prestwick compounds 
were plotted along three vectors derived from principal component analysis of a 
10-dimensional chemical descriptor matrix79 (Figure 9B). The principal 
components shown account for over 97% of the variance of all the parameters 
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used. This analysis reveals that the DAPs in the collection map to a sub-region of 
the chemical space spanned by the Prestwick compounds. 
Compounds were synthesized by the sequential nucleophilic substitution of 2,4-
dichloropyrimidines78. The products could be isolated in sufficient purity (>90% 
by LC/MS) and were generally obtained in 40-80% overall yield. 100 DAPs were 
synthesized and arrayed in formats compatible with high-throughput cell-based 
screens. Details of the chemical synthesis and characterizations are included in 
the Materials and Methods section. 
2.2.2. Screen Setup and General Results 
To analyze the effects of DAPs on cell division, I used BS-C-1 cells, a well-
characterized mammalian cell line employed in screens for cell division probes80. 
Cells were treated with compounds (20 M) for 4 hours, fixed and processed for 
immunocytochemistry. Images revealing the distribution of chromosomes and 
microtubules in compound-treated cells were acquired using an automated high-
throughput microscopy system. To identify compounds that would be useful 
probes for mechanisms specific to cell division, the 16 compounds that severely 
altered microtubule organization in non-dividing cells, as compared to control 
cells (Figure 10, Figure 11F,G), were eliminated. As a controI, I included in the 
DAP collection a compound that has been predicted to be a „frequent hitter‟ that 
targets multiple kinases (Figure 36D). I found that this compound strongly 
perturbs interphase microtubule organization, cell shape and nuclear structure, 
consistent with general toxicity. Three other compounds yielded crystalline 






Figure 10: Overview over Cell-Based Screening Results 
The phenotypes associated with the 100 DAPs were clustered by similarity. Categories of 
phenotypes for the initial analysis (10x magnification, 3 independent screens, to score as a “hit” in 
a category the same phenotype had to be seen twice or more): (1) Severe microtubule disruption 
(red), (2) Compounds that form aggregates (orange),  (3) Reduced mitotic index (light green). 
Scored if 2 or fewer mitotic cells per image (controls normally had ~10 mitotic cells). (4) Mitotic 
defects (green). These include spindle defects (2 or more cells per image field with perturbation) 
or chromosome alignment defects (5 or more cells per image field). (5) Compounds that did not 
meet the above criteria were considered inactive (yellow).The dose-dependence of the mitotic 
effects of the 22 compounds that either reduced the mitotic index or affected mitosis were 
determined (see inset). Phenotypes induced by compounds active at 10 M were analyzed 
further using higher resolution microscopy (see Figure 37A-F).  The corresponding chemical 
structure of each compound is abbreviated using the letter code provided in Figure 36C. 
 
non-specific protein binding activity81. The 22 DAPs that perturbed cell division 
and did not strongly affect microtubule organization in interphase cells were 
examined further (Figure 10). 
A wide range of cell division phenotypes, including changes in mitotic indices, 
mitotic spindles with perturbed or extra poles, bipolar spindles with perturbed 
architecture, monopolar spindles, improper chromosome alignment and defects 
in chromosome condensation were observed in treated cells (Figure 11A-E). 
The detailed results of the primary screen, including dose-dependence, are 
provided in the appendix (Figure 37A-F and Table 1). 
It is noteworthy that most of the cell division phenotypic categories described in 
genome-wide RNAi screens are also observed in this screen70,71. It suggests that 
a small number of compounds covering a limited drug-like region of chemical 




Figure 11: Cell Division Phenotype Space Is Effectively Spanned by a Small Collection of 
Diaminopyrimidines. 
(A-G) BS-C-1 cells treated with diaminopyrimidines (4 h) were fixed and processed for 
immunofluorescence microscopy to analyze tubulin (green) and chromosome (blue) distribution. 
Cell division phenotypes observed for different compounds included: (A) unperturbed spindles as 
in untreated cells, (B) bipolar spindles of improper size, (C) chromosome alignment defects, (D) 
monopolar spindles, and (E) mitotic spindles with pole defects or extra poles. Severe microtubule 
organization defects were also seen (F). (G) Unperturbed interphase microtubule arrays in a 
control interphase cell. The images show maximum intensity projections of deconvolved image-
series covering cell volumes. Scale bars, 10 m. 
 
2.2.3. Protein Targets of Compounds That Give Monopolar Spindles 
Identifying the targets of compounds selected in cell-based screens can be 
difficult82. Therefore, while interested in finding the targets of the 22 DAPs that 
perturb mitosis, I focused on a cell division phenotype that is better understood 
than most others. Monopolar mitotic spindles, where chromosomes decorate a 
radial microtubule array, were observed in cells treated with 4 different DAPs 
(Figure 37A-C). High-resolution analysis revealed that two of these compounds 
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also altered chromatin condensation and therefore these compounds were not 
analyzed further.  DAP-81, 2-[4-acetamidyl phenylamino]-4-[2-benzoyl 
phenylamino]-5-nitropyrimidine and DAP-49, 2-[benzothiazol-6-ylamino]-4-[indan-
5-ylamino]-pyrimidine (Figure 12A,B), are compounds that increased the number 
of monopolar spindles in treated cells in a dose-dependent manner (for this 
phenotype EC50 5 M and ~30 M, respectively) (Figure 12C,D).  
As DAPs have been extensively analyzed, I first examined if the compounds that 
resulted in monopolar phenotypes had known targets. DAP-81 has been reported 
to target a member of an evolutionarily conserved family of serine/threonine 
kinases called Polo-like kinases (hereafter, Plks)83. Plks are implicated in many 
aspects of cell division, including cell cycle progression, mitotic spindle assembly, 
and cytokinesis84. Of the four members of the Plk family, Plk1 has been 
extensively characterized and its link to mitosis most firmly established85. As 
reported previously, DAP-81 inhibits Plk1 in vitro (Figure 12E, IC50 of 0.9 M). 
Next, I tested whether DAP-49 also inhibits Plk1 to yield monopolar mitotic 
spindles, but no inhibition of kinase activity was observed at 100 M (Figure 
12F). Monopolar mitotic spindles are observed when cells have an improper 
number of centrosomes, microtubule organizing centers. This phenotype is also 
observed when centrosomes fail to separate86. Further analysis revealed that 
DAP-81 and DAP-49 do not change centrosome number in a 4-hour treatment 
(Figure 13A-E). Another  possible target is the kinesin Eg5, a microtubule-based 
motor protein that plays an essential role in centrosome separation in 




Figure 12: Monopolar Mitotic Spindles Are Induced by Two Diaminopyrimidines, Including 
One That Inhibits Polo-like Kinase 1 Activity in vitro. 
(A,B) Structures of DAP-81 and DAP-49, compounds that induce monopolar spindles. (C,D) 
Quantification of mono-, bi- or multipolar spindles in treated cells ( ≥ 100 cells for each data point, 
n = 3). (E) Recombinant Plk can phosphorylate casein, as analyzed by the transfer of 
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81 inhibits this activity in a dose-dependent manner (IC50 = 0.9 ± 0.3 M, n = 3, data was fit to a 
hyperbola). (F) DAP-49 (100 M) did not change phospho-casein levels, when compared to 




Figure 13: Monopolar Mitotic Spindles Induced by Two Diaminopyrimidines Do Not Result 
from Changes in Centrosome Number or Eg5 Inhibition. 
(A-D) After 4-hour-treatment with either DAP-81 (5 M), DAP-49 (20 M), monastrol (100 M) or 
vehicle (DMSO) BS-C-1 cells were fixed and processed for immunofluorescence. Images show 
DNA (blue), -tubulin (green) and -tubulin (red). Arrows point at -tubulin stained centrosomes. 
(E) Percentage of monopolar cells with 2 centrosomes after treatment. The centrosome number 
in treated cells with monopolar spindles was determined using -tubulin as a centrosome marker. 
(≥ 50 cells per compound, n = 3). (F) Eg5 dependent microtubule gliding velocity was measured 
in the presence of carrier (DMSO), DAP-81, DAP-49 (100 M each) (10 microtubules analyzed 
for each compound, n = 3). Monastrol (Mon.), an Eg5 inhibitor that induces monopolar mitotic 
spindles, was used as a positive control in the experiments. Error bars show s.d. The images 
show maximum intensity projections of deconvolved image-series covering cell volumes. Scale 
bar 5 m. 
 
microtubule sliding assays ruling it out as direct target of either DAP-81 or DAP-
49 (Figure 13F). While the target of DAP-49 is not known, these data indicate 
that DAPs with similar chemical substitutions can induce the same cell division 
phenotype by targeting different proteins. 
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2.3. Plk Inhibitors as Probes for Cell Division 
2.3.1. Polo-like Kinase in Mitosis 
Besides the cyclin-dependent kinases (Cdks), which function as master 
regulators of cell division, attention has shifted towards other protein kinases that 
cooperate with Cdks to allow for proper regulation and coordination of this 
intricate process. Among them, the Polo-like kinases (Plks) play a crucial role. 
They are a family of serine/threonine kinases that were first described as mutant 
in the fruit fly Drosophila melanogaster (polo) that gave an arrest in mitosis with a 
monopolar like spindle88,89, as well as in baker‟s yeast Saccharomyces cerevisae 
(cdc5)90. While there is only one Plk in fruit flies and baker‟s yeast, vertebrate 
species have several members, e.g. Plk1-4 in humans. They all have a similar 
structural organization with a kinase domain on the N-terminus and a polo-box 
domain(PBD) containing one or more so called polo-boxes (PBs) towards the C-
terminus of the protein (Figure 14). The kinase domain is highly conserved and 
its activity can be regulated by phosphorylation, whereas the PBDs recognize 
phosphopeptides and are important in substrate recognition and specificity. Prior 
phosphorylation of a Plk substrate by a so-called priming kinase is often 
necessary to allow PBD binding and subsequent phosphorylation by Plk.  Of the 
four members of mammalian Plks, Plk1 is the best studied and believed to carry 
out most mitotic functions associated with the single kinases Polo and Cdc5 in 





Figure 14: Domain Structure of Polo-like kinase 
Plk can be divided into two main parts, the N-terminal kinase domain and the C-terminal polo-box 
domain (PBD), which contains two (or one in case of Plk4) polo boxes (PB). The linker region 
contains a D-box motif that is required for the degradation by the anaphase-promoting 
complex/cyclosome. The activating phosphorylation site Thr210 in the T-loop of the kinase 





Before starting my studies, Plk1 had been implicated in a wide range of functions 
during mitosis. In mitotic entry, Plk1 had been shown to phosphorylate the 
Cdc25c phosphatase as well as Wee1 and Myt1 kinases, all resulting in the 
activation of the essential cyclin dependent kinase 1 (cdk1)/cyclin B complex 
(reviewed in 91). Plk1 has also been shown to be involved in centrosome 
maturation, as the recruitment of -tubulin, an essential microtubule nucleator, is 
decreased with reduced Plk1 activity92. Furthermore, Plk1 seems to be 
necessary for the assembly of bipolar mitotic spindles, as demonstrated by the 
emergence of monopolar spindles and abnormal bipolar spindles upon antibody 
injection or depletion by RNAi92-94. In addition to these roles, Plk1 is also involved 
in the control of sister chromatid cohesion, by phosphorylation and subsequent 
removal of subunits of cohesin, a necessary protein in this process95. 
Furthermore, in later stages of mitosis, Plk1 has been implicated in the activation 
of the anaphase promoting complex (APC/C)96,97. A role for Plk1 in cytokinesis 




Figure 15: Different Roles of Plk1 in Mitosis 




phosphorylation of proteins involved in cytokinesis, such as the motors Mklp198 
and Mklp299, or NudC100 and Rho exchange factor ECT2101 (summary in Figure 
15). 
Giving the multiple functions of Plk1 throughout mitosis, determining its specific 
role in each phase can be difficult. In the case of slow acting perturbations of 
Plk1, such as depletion by RNAi, knock-outs or mutants, only cumulative effects 
of Plk1 perturbation can be seen. To dissect Plk1‟s role especially in later stages 
of mitosis, faster-acting techniques coupled with high-resolution observations are 
necessary, which small molecule inhibitors can potentially provide. 
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Consistent with its multiple functions throughout mitosis, Plk1 expression is 
linked to cancer progression and prognosis85,102. Overexpression of the kinase is 
seen in many tumors such as carcinomas, lymphomas and melanomas and it 
may be a negative prognostic marker103. Interestingly, mutations in Plk1 in 
human tumors are not very common. Supporting a role of Plk1 in cancer is the 
finding that depletion by RNAi or transfection with a dominant negative form of 
Plk1 can induce apoptosis in cancer cells without necessarily affecting normal 
cells104-107. More recently, the use of specific small molecule inhibitors for Plk1 
showed promise in in vivo studies of tumor growth inhibition, further validating 
this kinase as potential cancer therapeutic target and encouraging the 
development of more small molecule inhibitors108.  
2.3.2. Available Inhibitors of Polo-like Kinase 
In addition to DAP-81, different inhibitors for Plk had been reported at the time of 
the study, including a styryl benzylsulfone (ON01910)109, and a benzothiazole-N-
oxide (here named BTO-1, Figure 16A,B)102,110. Before these inhibitors could be 
used to examine Plk function in cellular contexts, the following issues needed to 
be addressed. First, the small molecules should be able to recapitulate key 
aspects of loss-of-function phenotypes using other approaches. Second, the 
compounds should inhibit phosphorylation of known Plk substrates in cellular 
contexts. Third, at concentrations where the compound induces mitotic 
phenotypes and inhibits substrate phosphorylation, the specificity of the 




Figure 16: BTO-1 Inhibits Plk1 in vitro 
(A) Chemical structure of BTO-1, a benzothiazole-N-oxide. (B) Recombinant Plk1 can 
phosphorylate casein, as analyzed by the transfer of 
32
P. BTO-1 inhibits this activity in a dose-
dependent manner (IC50 = 8 ± 3 M, n = 3, data was fit to a hyperbola). 
 
More recently, two additional small molecule inhibitors of Plk1, cyclapolin111, a 
compound related to BTO-1, and BI-2536112 have been reported and used in 
studies of Plk1 function. Results from these studies are briefly discussed later on. 
2.3.3. Target Validation 
Phenotypes Resulting from Chemical Inhibition and RNAi Treatment 
Although the effects of depleting a protein using RNAi versus its chemical 
inhibition by small molecules are not necessarily expected to be identical, they 
can be reaffirming68. To compare the effects of chemical inhibition using BTO-1, 
ON01910 and DAP-81 to the loss of Plk function, human osteosarcoma cells 
(U20S) were treated with these compounds and direct comparisons to Plk1-RNAi 
treated cells were made. Confirming previous reports, Plk1-RNAi resulted in 
monopolar spindles with a reduced amount of -tubulin at their 
centrosomes93,94(Figure 17A,B). Treatment with DAP-81 and BTO-1 for 4h 




Figure 17: Comparison of Cell Division Phenotypes of Plk1-knock-down and Chemical 
Inhibitor Treatments. 
(A,B) U20S cells were either mock-transfected , or transfected with RNA-oligos against Plk1 as 
previously described
94
. After ~45 hours cells were fixed and processed for immunofluorescence. 
(C-F) After treatment of U20S cells for 4 hours with carrier (DMSO), 25 M DAP-81, 50 M BTO-
1, or 250 nM ON01910 the cells were processed as in (A,B). Overlays show DNA (blue), -
tubulin (green) and -tubulin (red).  The distribution of -tubulin is shown separately. The images 
show maximum intensity projections of deconvolved image-series covering cell volumes. 
Additional images are provided as Supplementary Material. (G) Western blots for Plk1 knock-
down after 45 hours (mitotic shake-off, p50 dynactin is used as a loading control). (H) 
Quantification of mono-, bi- or multipolar spindles in Plk1-RNAi transfected or mock-transfected 
cells is shown (≥100 cells for each data point, n = 3, error bar s.d.). (I,J) Quantification of mono-, 
bi- or multipolar spindles after 4h treatment with different concentrations of DAP-81 or BTO-1 
(≥50 cells for each data point, n = 3). Scale bars, 5 m. 
 
along with a reduction of -tubulin at the centrosomes (Figure 17C-E,H-J). It is 
noteworthy that similar to the RNAi of Plk1 in this cell type, and from other 
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reports93,94, variation in the inter-centrosomal distance was observed and 
centrosomes often dissociated from the center of monopolar microtubule arrays 
(Figure 38A-E for additional images). Treatment of U20S cells with ON01910 
(250 nM) resulted in multipolar spindles, as reported previously for HeLa cells109. 
In addition, interphase microtubule organization was perturbed and a measurable 
reduction of -tubulin staining at centrosomes (4-hour-treatment) was not 
observed (Figure 17F). Due to these differences in the phenotypes observed in 
ON01910 treated cells versus DAP-81, BTO-1 and Plk1 RNAi-treated cells, only 
DAP-81 and BTO-1 were used in further experiments. Both of these inhibitors are 
predicted to target the nucleotide pocket of the kinase and are therefore not likely 
to be selective for a specific Plk family member. Based on my RNAi experiments, 
and the known roles of Plk-family members84, I anticipate that these inhibitors will 
reveal phenotypes consistent with loss of Plk1 activity, particularly in the time-
frame of my live-cell experiments (see below). 
Inhibitor Activity in a Cell Line Expressing Fluorescent Tubulin 
To take advantage of the temporal control over protein function provided by cell-
permeable inhibitors, it is useful to match the perturbation time scales with high 
resolution analysis of cell division dynamics. A mammalian cell line stably 
expressing GFP--tubulin (PTKT) has been established as a model system to 
examine microtubule and chromosome dynamics during mitosis using multi-
mode microscopy113. Before chemical inhibitors and high-resolution imaging of 
PTKT cells could be used to examine Plk function in mitosis, characterization of 
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the effects of DAP-81 and BTO-1 in this cell type was required. A dose-
dependent increase in monopolar mitotic spindles was seen in treated cells 
(Figure 18A,B), with saturation at ~6 M DAP-81 and ~20 M BTO-1 (more than 
90% of mitotic structures being monopolar). Perturbed bipolar spindles, which 
had reduced spindle pole separation, were observed at lower concentrations. 
 
Figure 18: Quantitation of Monopolar Spindles and Mitotic Indices in DAP-81 and BTO-1 
Treated PTKT cells. 
PTKT cells were treated for 4 hours with DAP-81 or BTO-1 at different concentrations, fixed and 
immunostained for -tubulin and DNA. (A,B) Mitotic spindles were analyzed and the fraction of 
monopolar spindles was determined (≥ 50 cells for each data point, n = 3, error bar s.d.). 
Saturation was observed at 6.3 M DAP-81 and 20 M BTO-1 with 94% and 97% of the mitotic 
spindles, respectively, being monopolar. (C,D) The mitotic indices were determined for both 




Consistent with these spindle perturbations, a dose-dependent increase in mitotic 
index was seen for DAP-81 (Figure 18C). For BTO-1, the mitotic index did not 
change appreciably, suggesting that in addition to spindle perturbations, entry 
into mitosis may also be affected (Figure 18D, and data not shown). 
Although data for monopolar spindles indicated that ~6 M DAP-81 and ~20 M 
BTO-1 may be saturating concentrations, I needed to ensure that Plk is inhibited 
in cells at these inhibitor concentrations. Cdc25C has been reported to be a Plk1 
substrate and reagents for examining the phosphorylation of Cdc25C on serine-
198 are available114. Quantitative immunofluorescence was used to analyze 
phosphorylation levels of Cdc25C in DAP-81 and BTO-1 treated PTK cells. A 
dose-dependent reduction in phospho-Cdc25C was observed, with saturation at 
~6 M for DAP-81 and ~13 M for BTO-1 (Figure 19A-E). The observed 
differences in potency of either compound as compared to the data from the in 
vitro kinase assay are not unexpected. Factors such as using a native substrate 
and phosphatase activity in cells may contribute. Furthermore, differences in ATP 
concentration can also greatly affect the measured IC50 values, assuming 
competitive inhibition (Cheng-Prusoff equation)115. In summary, these data 
suggest that both inhibitors can block Plk kinase activity in cells at concentrations 




Figure 19: DAP-81 and BTO-1 inhibit the Phosphorylation of a Plk1 Substrate, Cdc25C, in 
Cells at Concentrations at which Phosphorylation of an Aurora B Kinase Substrate, 
Histone H3, Is Not. 
(A-E) PTK cells were treated for 1 hour with carrier (DMSO), DAP-81 (6.3 M) or BTO-1 (20 M), 
fixed and processed for immunofluorescence analysis of Cdc25C, Cdc25C phosphorylated at 
Ser-198 (pCdc25C) and DNA. Overlays show Cdc25C (green), pCdc25C (red) and DNA (blue). 
(D,E) Quantification of phospho-Cdc25C levels at centrosomes, normalized to Cdc25C, in DAP-
81 or BTO-1 treated cells. All scale bars, 5 m. (F-J) Histone H3 phosphorylation at Ser-10 (pH3) 
was analyzed in treated PTK cells. Cells were arrested in mitosis using monastrol (100 M), 
treated with MG132 (20 M) and carrier (DMSO), DAP-81 (6.3 M) or BTO-1 (25 M) for 1 hour, 
fixed and processed for immunofluorescence. Overlays show DNA (blue) and pH3 (red). (I,J) 
Quantification of pH3 levels in cell treated with either DAP-81 or BTO-1. ≥ 20 cells per condition 





Examining the Specificity of Plk Inhibitors in PTKT Cells  
The specificity of chemical inhibitors is a key issue that can limit their usefulness 
as probes of cellular mechanisms. To test the specificity of Plk inhibitors in 
cellular contexts I examined effects on two key mitotic kinases, Aurora kinases 
and cyclin-dependent kinases (Cdks)116. Ser10 on histone H3 is a known Aurora 
B phosphorylation site117. Quantitative immunofluorescence was used to 
examine histone H3 Ser10 phosphorylation. At 6.3 M DAP-81 or 25 M BTO-1 I 
found about 20% reduction in H3 phosphorylation compared to control cells 
(Figure 19F-J). At higher concentrations a further reduction in the H3 levels with 
DAP-81 was seen, consistent with some off-target activity of the inhibitor in this 
cell type.  
Aurora kinase inhibitors as well as Cdk inhibitors can drive cells out of mitosis, 
even in the presence of anti-mitotic agents that perturb microtubule 
polymerization or organization117,118. RNAi experiments have shown that loss of 
Plk function blocks cells in mitosis. Therefore, cells arrested in mitosis, by tubulin 
poisons or monastrol, would not exit mitosis upon treatment with a Plk specific 
inhibitor. Any off-target activity of a Plk inhibitor that blocks Aurora kinase or Cdk 
function would suppress the effects of other anti-mitotic agents. To use this 
assay as an additional test for specificity of Plk inhibitors, PTKT-cells were 
accumulated in mitosis by monastrol treatment for 3 hours. Then either DAP-81 
or BTO-1 were added and the mitotic state of individual cells was tracked by live 
imaging using phase-contrast microscopy. The Aurora kinase inhibitor 
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hesperadin and the Cdk inhibitor purvalanol A were used as controls in parallel 
experiments. As expected, hesperadin (500 nM) and purvalanol A (10 M) led to 
mitotic exit within 90 minutes (9/18 cell and 12/15 cells, respectively)13,117,118,  
whereas BTO-1 (20 M) and DAP-81 (6 M) treated cells remained in mitosis 
(cells exiting mitosis: 0/20 and 2/15, respectively). Together, these data indicate 
that at concentrations where DAP-81 and BTO-1 result in monopolar mitoses, 
inhibition of Aurora kinase or Cdk is not significant.  
Exhaustive tests of inhibitor specificity are typically limited to in vitro analyses 
with non-physiological substrates. These tests for all known mitotic kinases were 
not readily accessible to me. Instead, I took advantage of an alternative strategy 
involving the use of different chemical inhibitors of Plks in parallel experiments. It 
can be assumed that chemically unrelated inhibitors are less likely to have 
overlapping off-target effects, if any, particularly in the context of a narrow 
window of cell biology. The use of this strategy to examine the function of the 
Aurora kinases in cell division has been reported13and more recently this strategy 
was generally suggested to address specificity68. Therefore, BTO-1 and DAP-81 
were used in parallel experiments to further study Plk function in cell division. 
2.3.4. Plk Inhibition Changes Microtubule Dynamics in Dividing Cells 
Having validated the inhibitors in cellular context and addressed their specificity, I 
next used them to examine the effects of Plk inhibition in live cells with a focus on 
metaphase. The bipolar metaphase spindle is a steady-state structure that can 
maintain its shape and size for hours in the face of constant microtubule 
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turnover2. I used near simultaneous spinning-disc confocal and differential 
interference contrast (DIC) microscopy to study microtubule and chromosome 
dynamics in live PTKT cells. Cells at metaphase, with established bipolar 
spindles, were located and DAP-81 was added (6.3 M). Within minutes, the 
bipolar spindle started collapsing (3 cells of 6 imaged). In the 3 other cases, cells 
proceeded with chromosome segregation, most likely due to anaphase initiation 
prior to equilibration of compounds at inhibitory concentrations in the imaged cell. 
In subsequent experiments, addition of the proteasome inhibitor MG132 blocked 
anaphase. In every case (n = 15) DAP-81 treatment inhibited the maintenance of 
spindle shape. The two spindle poles moved closer together and the thick 
microtubule bundles attaching the poles to the chromosomes, called kinetochore-
fibers (K-fibers), shortened. Over time, chromosomes that were aligned at the 
metaphase plate changed their positions to distribute around the unseparated 
spindle poles (Figure 20A-L). In the time-course of the experiment (1 hour, to 
limit photobleaching), every spindle imaged shortened, and 4 cells formed 
monopolar structures. The V-shape of the moving chromosomes indicated that 
pulling forces acted on chromosomes through K-fibers and that spindle 
connections were maintained during the disassembly of these microtubules after 
Plk inhibition (Figure 20M). Similar results were obtained in BTO-1 treated cells 
(Figure 20N-W, n = 7). 
A striking difference between the initial bipolar spindle and the collapsing spindle 
was the persistence of microtubules that extended from the spindle poles to the 




Figure 20: Polo-like Kinase Activity Is Required for the Maintenance of Spindle Bipolarity. 
GFP--tubulin expressing cells were imaged using near simultaneous 3D spinning-disc confocal 
microscopy and DIC, to track microtubule (A-F,N-R) and chromosome distributions (G-L, S-W), 
respectively. (A-L) A cell at metaphase with a bipolar spindle was located and DAP-81 (6.3 M) 
was added (t = 0 min). The shortening of chromosome-associated microtubule fibers (arrow 
heads) and the formation of microtubule bundles, not associated with chromosomes and 
extending away from the spindle (arrows), are indicated. MG132 (20 M) was used to accumulate 
metaphase spindles. (M) An example of a V-shaped chromosome observed in treated cells is 
highlighted (from outlined region in panel (L), asterisk marks the primary constriction). (N-W) In a 
parallel experiment, BTO-1 (20 M) was added (t = 0 min) to cell at metaphase and microtubule 
and chromosome dynamics were examined. Time is in min:sec. Scale bars, 5 m. 
 
microtubules interacts with the cell cortex. This array is referred to as astral 
microtubules, which are typically single microtubules that cannot be readily 
resolved by light microscopy due to low fluorescence intensities and fast 
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movements in 3-D86. In cells treated with either inhibitor, some microtubule fibers 
that emanated from the spindle pole and made contact with the cell cortex were 
very intense in confocal sections, indicating that many microtubules were 
bundled to form these fibers. Analysis using kymography in DAP-81 treated cells 
showed that unlike astral microtubules in untreated cells, these fibers appeared 
to be stable over several minutes (Figure 21A-H). In collapsing bipolar spindles 
these microtubule bundles often were not straight, but buckled, suggesting that 
these fibers were likely pushing against the cell cortex119. Together, these data 
reveal that Plk function is required for the stabilization of chromosome-associated 
microtubule bundles and the maintenance of dynamic astral microtubules.  
The normal shape and size of the bipolar spindle is maintained through a 
balance-of-forces generated at the cell cortex and at different sites within the 
spindle120. While the observed changes in microtubule dynamics were associated 
with the spindle collapse, it was unclear how the balance of forces maintaining 
spindle shape was perturbed. To examine this, I measured the distance between 
sister kinetochores on individual chromosomes, a read-out for spindle-generated 
forces acting at chromosomes (Figure 21I-L)121,122. In untreated bipolar spindles, 
the inter-kinetochore distance (centromere stretch) was 2.3 ± 0.5 m. In the 
presence of nocodazole (33 M), spindle microtubules were absent and as 
expected, inter-kinetochore distances were reduced to 1.4 ± 0.3 m. In collapsing 
bipolar spindles in cells treated with DAP-81 or BTO-1, I found the inter-
kinetochore distance to be 1.9 ± 0.3 m and 2.3 ± 0.3 m, respectively. 




Figure 21: Plk Inhibition Leads to Collapsing Spindles with Stable Astral Microtubule 
Bundles without Loss of Centromere Tension. 
(A-H) Stability of microtubule bundles pointing away from the chromosomes (astral microtubules) 
that formed after treatment with DAP-81 (6.3 M) was assessed using kymographs, computer-
generated montages prepared by aligning the same region imaged in a time-lapse experiment, 
such that the spatial and temporal components are presented in the x- and y-axes, respectively. 
For these experiments, inhibitor-treated PTK--tubulin cells were imaged by 3D confocal 
fluorescence microscopy at 20 second time-intervals for 5 minutes. (A-D) Mitotic spindles at the 
start of the recording. The regions used for preparing kymographs are indicated (white bar). (E-H) 
Kymographs for each cell (A-D). Stable microtubule bundles are visible as regions of 
fluorescence intensity that persist for several minutes. (I-L) Inter-kinetochore distances were 
measured in PTK--tubulin cells treated with carrier (DMSO), DAP-81 (6 M), BTO-1 (20 M) or 
nocodazole (33 M) for 45 minutes. Cells were fixed and stained for -tubulin (green) and 
CREST-antigen (red). Distances between kinetochore pairs in mitotic cells (center-center of 
CREST intensity) were measured in three dimensions using deconvolved image planes. (I-K) 
Representative images are shown as maximum intensity projections of deconvolved image-series 
covering cell volumes. Arrows indicate kinetochore pairs.  (L) Average inter-kinetochore distances 
(≥67 kinetochore pairs total from ≥9 cells total for each compound, error bar s.d.). MG132 (20 M) 





that they do not increase in response to higher forces, my data suggest that the 
forces acting on chromosomes are high in Plk inhibitor treated cells, but no 
greater than those acting in control spindles. Therefore, the spindle collapse is 
not likely to be a consequence of an increase in the polewards forces acting at 
chromosomes, but more likely to result from changes in the forces keeping 
spindle poles apart. 
I next examined the consequence of activation of Plk in treated cells, after relief 
from chemical inhibition. Based on the chemical structure of DAP-81, I expected 
that the inhibition of the kinase activity would be reversible. To test this idea, the 
cell culture medium during live microscopy of DAP-81 treated cells was replaced 
with Plk inhibitor-free media. I observed that upon relief from inhibitor treatment, 
microtubule dynamics changed.  The chromosome-associated K-fibers 
lengthened, and the astral microtubule bundles destabilized resulting in a typical 
dynamic astral microtubule array (Figure 22A-E, arrows). Furthermore, 
chromosomes repositioned at the metaphase plate at the center of the spindle 
(Figure 22F-J).  Exchanging the medium to remove BTO-1 did not lead to a 
recovery, indicating that this inhibitor may act irreversibly. Based on the chemical 
structure of BTO-1 this is not unexpected and irreversibility of this class of 
inhibitors has also been observed by others111. These data suggest, that 
changes in microtubules dynamics and the associated changes in spindle 
geometry and chromosome-spindle attachments are dynamically maintained 




Figure 22: The Selective Stabilization of Astral Microtubules and the Destabilization of K-
fibers Can Be Reversed by Plk Activation 
GFP--tubulin expressing cells were imaged using 3D spinning-disc confocal microscopy and 
DIC, to track microtubule (A-E) and chromosome distributions (F-J), respectively. After treatment 
of a cell with DAP-81 (6.3 M), the cell culture media was replaced with Plk-inhibitor free media 
(t=0 min). The chromosome-associated microtubule fibers (arrow heads) lengthened and the 
microtubule bundles extending away from the spindle and chromosomes (arrows) disassembled, 
leading to a bipolar spindle. MG132 (20 M) blocked anaphase onset after relief from DAP-81 
treatment. Time is in min:sec. Scale bar, 5 m. 
 
2.3.5. Discussion 
The error-free segregation of chromosomes during cell division depends on the 
proper functions of a large number of proteins at specific times and cellular sites. 
The cell division phenotypes observed in cells treated with DAPs are expected to 
be linked to the functions of a subset of these proteins. Recent genome-wide 
protein knock-down screens and other RNAi studies have revealed the cell 
division phenotypes caused by the loss of a large number of proteins, and have 
linked many proteins to individual phenotypes71. For example, multipolar spindles 
are observed upon depletion of ch-Tog123, RanBP2124, Tpx2125, and astrin126. 
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Chromosome alignment defects are seen after RNAi of Aurora kinases127, Cenp-
F128, Kid129, and haspin130. Monopolar spindles can result from the loss of 
function of different proteins as well. Activity assays for proteins linked to this 
phenotype, such as Eg5 and Plk, have been useful in determining the 
mechanisms of action of small molecule inhibitors that induce monopolar 
spindles. Therefore knock-down data can help streamline the identification of the 
targets of compounds selected from phenotype-based screens. However, it 
requires that assays are available for the activities of different proteins whose 
functions are linked to a phenotype.  
By combining the use of cell-permeable inhibitors that act on fast time scales with 
high-resolution microscopy I found that Plk contributes to the formation of bipolar 
mitotic spindles by differentially regulating the dynamics of microtubule 
populations in the cell. Previous studies have shown that K-fibers in mammalian 
cells are crosslinked bundles of ~28 microtubules that are believed to be more 
stable than other spindle microtubules131. This has been directly assayed in a 
number of different ways3, including chemical perturbations, increasing pressure 
on cells or changing temperature. Centrosome-associated microtubules, called 
astral microtubules, represent a subset of spindle microtubules that are generally 
believed to be more dynamic and not bundled by cross-linking proteins86. Upon 
Plk inhibition, the normally stable K-fibers disassemble and the dynamic 
centrosome fibers get stabilized and bundled, indicating that Plk activity plays a 
key role in maintaining the spatial asymmetry in microtubule dynamics in dividing 
cells. While the emergence of stabilized astral microtubules is visible, their origin 
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is not clear. Three pathways could lead to their formation: centrosome-mediated 
nucleation, kinetochore-mediated nucleation, or nucleation mediated by existing 
microbules132-135. The absence of kinetochores on the end of the stabilized 
bundles indicates that kinetochore mediated nucleation is most likely not 
relevant. Differentiation between the two other possibilities is difficult and would 
require more detailed studies of microtubule dynamics in these bundles, which 
are beyond the scope of my work. Such spatially-specific regulation of 
microtubule polymerization has also been proposed for the role of Aurora kinases 
in the disassembly of incorrect chromosome-spindle attachments and the 
stabilization of the proper attachments13. In a similar fashion, Plk could affect the 
phosphorylation state of microtubule stabilizers or destabilizers in normal bipolar 
spindles, in a spatially specific manner to help establish the differentiation 
between stable K-fibers in the mitotic spindle and dynamic astral microtubules. 
Exactly which effectors of microtubules are involved is not yet clear, but further 
studies using small molecule inhibitors might help to identify relevant Plk 
substrates. 
The bipolar spindles can collapse into monopolar structures upon Plk inhibition 
because of two different force-generating mechanisms. It is possible that the 
depolymerizing K-fibers, which are associated with unseparated sister 
chromatids, can generate a pulling force that draws the two spindle poles of a 
bipolar spindle together. Alternatively, hyper-stabilized astral microtubules could 
interact with the cell cortex to push the spindle poles together. While it is possible 
that both mechanisms contribute to the spindle collapse, the astral microtubule 
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bundles observed after Plk inhibition buckle upon cortical interactions, suggesting 
that pushing forces may be more important. Consistent with this hypothesis, I find 
that upon activation of Plk after relief from chemical inhibitor, bipolar spindle 
formation is closely linked to the disappearance of these stable microtubules. In 
addition, the observed tension across kinetochores in collapsing spindles 
indicates that spindle pulling forces are active, but not likely to be greater than in 
untreated cells. It is likely that combining microscopy studies with physical 
manipulation of the spindle and chromosomes will be necessary to unravel the 
roles of Plk in regulating the balance of forces that maintain spindle 
organization87,121.   
Small molecule probes for the different proteins that play key roles in cell division 
will help clarify the mechanisms required for the stable propagation of genomes. 
My studies suggest that one approach to obtain such probes is to explore 
thoroughly the chemical space around known bio-active compounds. Consistent 
with this idea, recent studies have shown that small changes in substitutions on 
kinase inhibitors can not only change their selectivity for different classes of 
kinases, but can also lead to inhibitors for completely unrelated proteins63. The 
hydroxyl modification of a Src-kinase inhibitor, which instead leads to carbonyl 
reductase inhibition, is a striking example how small changes in chemical 
structure can lead to divergent biological activity136. The number of different 
phenotypes observed in dividing cells treated with closely related 
diaminopyrimidines suggests that this scaffold can target several different 
proteins. In addition, a single phenotype can be induced by DAP-49 and DAP-81, 
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which target different proteins. I anticipate that further exploration of the chemical 
diversity of diaminopyrimidines will lead to new probes for cell division proteins. 
The fact that these compounds map to the chemical space occupied by drug-like 
molecules suggests that their further development into therapeutic agents could 
succeed. Current synthesis efforts generating diverse compounds should lead to 
other versatile scaffolds74.  It will be important to test if other „privileged scaffolds‟ 
can also effectively span cell division phenotype space. 
2.3.6. Recently Reported Work Using Polo-like Kinase Inhibitors 
After completing my studies on Polo-like kinase using DAP-81 and BTO-1, 
several new small molecule inhibitors have been reported and used to answer 
questions about Plk‟s role in cell division, with a particular focus on later stages 
of mitosis. 
McInnes et al. used a benzothiazole related to BTO-1, termed cyclapolin 1, to 
answer questions regarding Plk at metaphase111. In addition to fixed cell 
experiments that resulted in abnormal bipolar mitotic spindles, Mcinnes et al. 
carried out live-cell experiments on Drosophila S2 cells that clearly demonstrated 
the collapse of bipolar spindles into monopolar spindles upon Plk inhibition, 
corroborating my findings. In addition they found that Plk inhibition led to a 
reduced recruitment of -tubulin to the centrosomes as well to a reduced ability of 
centrosomes to nucleate microtubules in vitro. 
Lenart et al. employed BI 2536, a nanomolar and highly specific inhibitor of Plks, 
to look at Plk‟s role in mitotic entry as well as prophase and metaphase112. This 
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team found that inhibition of Plk led to a delay in mitotic entry but not a block, and 
that Plk activity was necessary to form stable microtubule attachments during 
prometa- and metaphase leading to a spindle-checkpoint arrest in its absence. 
As with the other reported compounds and my findings, the compound gave a 
monopolar spindle phenotype. 
Continuing the work with BI 2536, Petronczki et al. reported interesting details 
about Plk‟s function in cytokinesis137. They added the small molecule inhibitor 20 
minutes after metaphase in live-cell experiments and observed problems in 
cytokinesis, markedly the inability to assemble the actomyosin ring necessary for 
contraction. This may have been caused by localization defects of several 
proteins, since the authors showed that in the absence of Plk activity Plk itself, 
RhoA, its exchange factor Ect2 as well as Mklp2 failed to localize to the midzone. 
I also provided BTO-1 and BI 2536 to collaborators to look at the role of Plk in 
anaphase and cytokinesis, areas I have personally not explored138. Ian Brennan 
in Aaron Straight‟s lab found that upon inhibiting Plk activity at anaphase onset, 
chromosome movement in anaphase A was unaffected, but the spindle 
elongation typical for anaphase B was inhibited. Focusing on cytokinesis, it was 
also shown that Plk activity was necessary for assembly of the contractile ring. 
Similarly to findings from other groups, it was shown that RhoA and its exchange 
factor Ect2 mislocalized, and that crucial components of the acto-myosin ring, 
like anilin, did not get properly recruited. 
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Comparable results were also obtained by Burkard et al. using a slightly different 
approach30. Knocking out the endogenous Plk1 and replacing it with an ATP-
analog sensitive allele allowed the authors to control Plk1 activity by using an 
ATP-analog as a small molecule inhibitor. Employing this „bump-hole‟ technique 
they showed that Plk1 activity was necessary for cytokinesis since cleavage 
furrow formation was blocked, accompanied by mislocalization of Plk1 as well as 
Ect2, in agreement with the aforementioned reports. 
Using the advantage and availability of small molecule inhibitors the roles of Plk 
throughout mitosis could be better defined. In addition to its role in spindle 
maintenance, its roles in anaphase and cytokinesis are now better understood. 
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3. A Phenotypic Screen for Inhibitors of Organelle 
Transport 
3.1. Introduction 
3.1.1. Organelle Transport and Motor Proteins 
Intracellular transport in the cytoplasm of eukaryotic cells is a fundamental 
biological process required for the correct distribution and positioning of 
organelles such as mitochondria or peroxisomes, and for macromolecular 
complexes, such as mRNPs and chromosomes in mitosis. In addition, 
intracellular transport processes can rapidly adjust and maintain the molecular 
architecture, which cannot be achieved with passive transport processes such as 
diffusion alone, on the typical length scale of eukaryotic cells.  
To generate the forces necessary to move “cargo” in the viscous cytoplasm of 
cells, two major mechanisms are used: the polymerization and depolymerization 
of cytoskeletal subunits such as tubulin or actin, and the work provided by 
molecular motor proteins that use ATP-hydrolysis as energy source. These 
motors can be categorized into three classes: dyneins and kinesins, which move 
along microtubules, and myosins, which move along actin filaments139.  
To allow transport of a specific cargo to occur to a specific location within the cell 
at a precise point in time, prerequisites to create order within a cell, regulation of 
intracellular transport is essential. As one would expect, the regulation is complex 
and can occur on several different layers. First, specificity of the process can be 
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achieved by binding of the motor proteins to a defined set of cargoes, which is 
often mediated by adapter proteins, such as dynactin in the case of kinesin or 
dynein. This specificity can confer the proper targeting of organelles to certain 
sites within the cytoplasm, e.g. the transport of mitochondria to regions of 
increased ATP-usage. Second, the movement of cargo can be activated or 
inhibited depending on a certain physiological state of the cell, e.g. control of 
chromosome movement in mitosis 140,141, cessation of cytoplasmic organelle 
movement during cell division142-144, as well as lipid droplet movement during 
embryonic development in Drosophila145. One of the most remarkable cases of 
regulated movement of organelles are pigment organelles (melanosomes) in the 
pigment cells (melanophores) of lower vertebrates (described below). 
The study of factors involved in producing and regulating movement of cellular 
cargo remains one of the key challenges of cell biology. While many of the motor 
proteins are known, the mechanisms of their regulation and coordination are 
generally not well understood. Therefore, suitable methods for the identification 
of the molecular agents as well as detailed functional analysis in cellular contexts 
are of great importance. 
Given the fact that intracellular transport processes occur on a fast time scale, 
small molecules coupled with live imaging microscopy would be well suited to 
better understand them. However, at the moment the available number of small 
molecules is limiting. For instance, as inhibitors of motor proteins only 
blebbistatin17, which targets myosin II, and various inhibitors of mitotic kinesin 
Eg5 have been used significantly55. Therefore the identification of additional 
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small molecules that can lead to a better understanding of intracellular transport 
remains highly desirable. To achieve this goal, a screening system for inhibitors 
of intracellular transport would be beneficial. 
3.1.2. The Xenopus Melanophore System 
Pigment cells are a suitable system to study organelle transport, since their main 
physiological function is the coordinated redistribution and bidirectional 
movement of pigments in response to defined chemical signals.  Pigment cells 
are generally referred to as chromatophores and  can be classified into two major 
classes: cells that undergo pigment redistribution or structural changes that result 
in a physiological color change („rapid color changes based on the intracellular 
mobilization of pigment-containing organelles‟146) and pigment-producing cells 
where the pigment is transported to other cell types that take it up, resulting in a 
morphological color change („color changes result from changes in the number 
and synthetic activity of integrumentary pigment cells‟147). Pigment cells which 
contain black pigments are referred to as melanophores, in the case of the rapid 
acting cells common in invertebrates, fish, and amphibians, while the slow acting 
cells, common to birds and mammals, are referred to as melanocytes146. The 
organelles containing black pigment are known as melanosomes. 
In the case of melanophores from the African Clawed Frog (Xenopus Laevis), the 
cells contain a large number of melanosomes in their cytoplasm that can either 
cluster around the center of the cell in the perinuclear region (aggregated state) 
or be homogeneously dispersed (dispersed state)(Figure 23A). The net effect of 
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the differences in pigment distribution in the skin is a lighter color in case of the 
aggregated cells and a darker color in the dispersed case. 
To allow a switching between these two physiological states, hormones are used 
that affect the intracellular cyclic AMP (cAMP) level via a signaling cascade. 
Melatonin leads to a decreased level of cAMP, whereas melanocyte stimulating 
hormone (MSH) results in an increased level of cAMP, promoting aggregation 
and dispersion, respectively. A high-throughput screening approach in 
melanophores using the degree of dispersion as read-out can be envisioned, 
which is aided by the access to an immortalized Xenopus melanophore cell 
line148. Screening for inhibition of either direction of organelle movement is 
possible and enough cell-free extract for biochemical experiments as well as 
target identification studies can be obtained149. Furthermore, melanosomes are 
 
Figure 23: Hormones, Signals, and Motors Involved in Pigment Transport in 
Melanophores. 
(A) Aggregation is induced by melatonin, which decreases the cAMP concentration, and 
dispersion by melanocyte-stimulating hormone (MSH). (B) Aggregation is performed by 
cytoplasmic dynein while dispersion requires two motors, kinesin II and myosin V. Figure adapted 
from Vladimir Gelfand. 
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easily observed in bright-field microscopy, and the obtained data can be easily 
subjected to computational analysis. Moreover, the melanophore system has 
been extensively studied as a model for organelle motility (reviewed in 150) 
resulting in the following relevant findings for my work: (1) Correct movement of 
melanosomes requires the presence of microtubules and actin filaments as 
cytoskeletal components151-153(Figure 23B). (2) Gradient purified melanosomes 
contain three types of molecular motor proteins on their membrane surface: 
heterotrimeric kinesin-II, a plus-end directed microtubule motor, cytoplasmic 
dynein, a minus-end directed microtubule motor, and myosin-V, an actin 
motor149,152 (Figure 23B). (3) Movement of isolated melanosomes has been 
reconstituted in vitro 149,152,154. (4) Components of the regulatory pathway from 
hormones and hormone receptors to protein kinase A (PKA) are well known155. In 
addition assays and reagents are available to determine whether a compound 
targets these proteins. Therefore, secondary screens can be used to select 
compounds that act downstream of PKA, a part of the signaling pathway not yet 
characterized (Figure 24). 
This system provides several additional factors that are advantageous to a 
chemical screen. The organelle motility in melanophores relies on the relatively 
stable interphase microtubules, and is therefore much less sensitive to more 
subtle effects on microtubule dynamics, which are particularly seen in cell 
division screens55,156. Furthermore, inhibitors of vesicle formation and membrane 
fusion are not selected for in the case of melanophores, unlike a screen using 
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membrane transport between the endoplasmic reticulum and the Golgi apparatus 
as read-out157. 
While the advantages listed above make the melanophore system ideal to find 
inhibitors for organelle motility, the potential insights and compounds obtained 
 
Figure 24: Signaling in Melanosome Aggregation 
Protein dephosphorylation of unknown targets, which leads to aggregation of melanosomes, is 
dependent on a serine/threonine dependent phosphatase that becomes active when PKA is 
inactivated. Gi - inhibitory G-protein, cAMP – cyclic AMP, 5‟-AMP – adenosine 5‟-monophosphate. 







are expected to be applicable to the wider field of biological systems. 
Considering that many kinds of membrane organelles are associated with (at 
least) two microtubule based motor proteins of opposite polarities and a 
myosin158-161, this assumption appears reasonable. Moreover, coordination of 
plus- and minus-end directed organelle movement on microtubules is not only 
observed in melanophores, but in other cell types as well162-164. In summary, the 
study of melanosome transport should uncover general mechanisms of organelle 
transport in eukaryotic cells. 
In summary, establishing and using melanophores as a cell-based screening 
system for inhibitors of intracellular transport may be useful in identifying 
compounds that are of wider use in the field of intracellular transport and may 
help to gain a better understanding of this dynamic and highly regulated process. 
3.2. The Screen 
3.2.1. Screening for Inhibitors of Aggregation 
With hormones available that either induce aggregation or dispersion in 
melanophores, melatonin and MSH, respectively, screening can be carried out 
for inhibitors of transport in either direction. Screening was focused on inhibitors 
of aggregation for two main reasons: The upstream signaling in aggregation is 
less complex: it relies only on PKA whereas dispersion can be influenced by PKA 
and protein kinase C155, and aggregation mainly relies on the function of only one 
motor, cytoplasmic dynein. Both these facts help to simplify follow-up studies, 
especially considering that inhibitors of PKA and purified dynein were available. 
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In addition, a small molecule inhibitor of cytoplasmic dynein would be especially 
useful since this multisubunit motor protein participates in a large number of 
transport processes other than melanosome movement, such as positioning and 
assembly of the mitotic spindle, interflagellar and viral transport, as well as 
nuclear envelop breakdown139.  
The initial screen in a high-throughput format was developed and carried out by 
Michael Lampson in the laboratory. Briefly, melanophores are dispersed by 
treatment with MSH to obtained uniformly dispersed cells. Next, the screening 
compounds are added and after a short incubation period the melanosome 
aggregation is stimulated by treatment with melatonin. After fixation, the fields of 
cells can be imaged using an automated image acquisition set-up, followed by 
computational analysis with „dispersion index‟ as readout (see Figure 25). This 
procedure can be carried out in a 384-well format, allowing a high throughput. 
(Figure 25) 
3.2.2. Potential Targets of Active Compounds 
Considering the inhibition of aggregation as the primary readout in the 
melanophore system, three major modes of action of the compounds can be 
envisioned, which need to be distinguished in follow-up screens. First, the 
compound could lead to an arrest of metabolic activity and therefore to a stop of 
ATP-dependent movement of aggregating melanosomes. Second, organelle 
movement could be inhibited in a more specific way by inhibiting either molecular 
motors directly, acting on the motor-cargo interaction, or affecting the necessary 
cytoskeletal components for motor activity. Third, the movement of melanosomes 
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could be intact but their bias towards the perinuclear region is lost, indicating 
alteration of signaling events necessary for the coordination of movement. Of 
these potential target classes for compounds, two groups are of particularly 
relevant in understanding intracellular transport. The first are direct inhibitors of 
motor proteins, especially given the fact that only very few small molecule 
inhibitors are known so far17,55. The second group consists of compounds that act 
in the signaling pathway downstream of PKA, since this region is not well 
characterized155. A flow scheme for selecting these particular compounds of 
interest is shown below (Figure 26).  
 
Figure 25: Inhibitors of Aggregation Can Be Identified by High-Throughput Imaging 
The pre-dispersed cells are incubated with the test compound for 30 minutes followed by the 
treatment with melatonin to stimulate aggregation. After one hour the cells are fixed and images 
of the wells are acquired by an automated system. The images are then processed and inhibitors 
of aggregation can be detected and quantified by a high ratio of small objects (single dispersed 
melanosomes, Nsmall) versus large objects (aggregates of melanosomes in the perinuclear region, 





Figure 26: Flow Chart Outlining Potential Targets and Screening Strategies for Inhibitors 
of Aggregation 
Light bulbs indicate satisfactory endpoints. Y- yes, N – no. 
 
3.2.3. Selection of Compound Collections 
The first primary screen used a commercial collection of 15000 compounds 
(Chemical Diversity, Inc., ”Chemdiv”) available through the Rockefeller University 
High-Throughput Screening Center. This collection contains about 125 
combinatorial templates with up to 200 compounds per template. While this 
collection has no focus towards a particular class of target proteins it mostly 
consists of heterocyclic compounds that follow Lipinski‟s Rule of Five43 to 
increase the chance of finding small, cell-permeable, drug-like inhibitors.  
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In addition to an unbiased screen, the encouraging results from the DAP-
collection in the screen for cell division phenotypes suggested that a biased 
approach using a „privileged scaffold‟ might be successful as well. Therefore, 
compounds from the DAP-collection were tested in the melanophore screen. This 
should allow us to address several questions regarding the use of DAPs. First, is 
the hit rate increased in the case of DAPs as compared to an unbiased library? 
Second, are DAPs potentially useful inhibitors in the context of intracellular 
transport? Third, what is the cross-correlation between hits in both screens?  
With a primary screen, follow-up assays and compound collections in hand, the 
identification of inhibitors of intracellular transport could be carried out. 
3.3. Screen Results 
3.3.1. Overview over Results from the “Chemdiv” Collection 
The screen of the ~15000 compounds from the chemical diversity collection was 
carried out in triplicate for inhibitors of aggregation following the procedure 
outlined above. Compounds that showed activity in any of the screens were 
retested, leading to 156 confirmed hits from this library in the primary screen. 
After elimination of tubulin depolymerizers by evaluation of immunofluorescent 
tubulin stains, inhibitors were grouped into the two major classes: compounds 
that block aggregation by stopping organelle movement in cells, and compounds 
that block aggregation without stopping organelle movement. Compounds that 
did not stop movement most likely acted as regulators in the signaling cascade 
and were further differentiated as either upstream or downstream of PKA. For 
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this purpose, the compound‟s effect on aggregation was tested in the presence 
of a constitutively active PKA-inhibitor, PKI, a peptide that was transfected into 
melanophores. Overriding of the aggregation induced by PKI indicated that the 
compounds most likely acted downstream of PKA165(Figure 27A,B). The 
summary of results is shown below (Figure 28). 
A potential target for the 19 compounds that stopped organelle movement is 
cytoplasmic dynein. Dynein inhibition could be easily tested by an in vitro 
microtubule sliding assay using purified components from bovine brain166. In this 
assay the motor protein is immobilized onto a glass coverslip followed by addition 
of fluorescently marked microtubules that bind to the motor. In the presence of 
ATP the microtubules will „slide‟ across the surface driven by dynein. None of the 
compounds, however, inhibited this dynein driven motion at concentrations of up 
to 125 M. 
 
Figure 27: Compounds Downstream of PKA Induce Dispersion Even if PKA Is Inhibited. 
Cells were transfected with a plasmid that encodes PKA inhibitor PKI and a tag
165
. Transfected 
cells were treated for 30 min with 20 M compound (A) or DMSO (B) as control and fixed. The 
compound induces dispersion of melanosomes even in the cells with inhibited PKA. The image is 
a superposition of two images, brightfield (melanosomes) and immunofluorescence (tag). Figure 





Figure 28: Overview of Results from the Screen of the Chemdiv Library 
In addition to the number of compounds chemical structures of examples for each major class of 
hits are shown. 
 
3.3.2. 37P11 Blocks Aggregation But Does Not Stop Organelle Movement 
In the absence of a reliable assay for the testing of the direct inhibition of other 
motor proteins other than dynein, namely kinesin II, I focused my attention on the 
second class of hit compounds, the ones that did not stop organelle movement 
and therefore putatively acted on the signaling cascade. Of the compounds 
selected and tested, 37P11 appeared promising. It was able to overcome PKA 
inhibition, indicating that its primary target is downstream of this kinase. 




Figure 29: 37P11, a Reversible Inhibitor with an IC50 of 21M, Acts Downstream of PKA 
(A) Titration curve for 37P11 in the primary assay with dispersion index as read-out (experiment 
done in triplicate). (B) After removal of 37P11 (washout) the melanosomes are able to aggregate, 
the cells are nearly fully recovered as compared to the control case (DMSO). (C) Transfection of 
melanophores with PKI leads to tight aggregation. Treatment of cells with either 37P11 or 
nocodazole partially overcome that effect whereas MSH cannot, indicating that 37P11 acts 
downstream of PKA. 
 
easily amenable to analog synthesis for target identification studies (chemical 
structure see Figure 28). 
Properties of 37P11 in Primary and Secondary Assays 
For subsequent studies 37P11 needed to be characterized further in regard to 
potency as well as potential protein targets. Since the molecular target of this 
molecule was unknown, the cellular activity was the only relevant read-out for 
potency. A titration was carried out in triplicate in the primary assay yielding an 
IC50 value of 21 M using the dispersion index as quantitation (Figure 29A). In 
addition, removal of the compound by washout in the same assay clearly 
demonstrated that the observed inhibition was reversible (Figure 29B). The 
inhibition of aggregation experiments were also carried out using live-cell 
microscopy, revealing a loss of bias towards aggregation despite relatively 
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normal organelle motility (data not shown). As the next step, 37P11 was tested in 
the PKA inhibitor-assay (Figure 27A,B). Although the quantitation showed only a 
relatively modest effect of the compound in overcoming aggregation, the effect is 
comparable to that of nocodazole, which is known to depolymerize microtubules 
and to act downstream of PKA (Figure 29C). MSH, an upstream signal in 
aggregation shows no effect in the presence of PKA-inhibitor, as expected. 
These data indicate that 37P11 blocks aggregation without stopping the 
movement of melanosomes and that the target of 37P11 may be a regulatory 
protein downstream of PKA. 
Design and Synthesis of 37P11 analogs for SAR Studies 
After identification of 37P11 as compound that acts downstream of PKA, I was 
interested in determining its molecular target. Of note, very similar compounds 
are known as antagonists of mammalian vanilloid receptors, particular type I 
vanilloid receptors (VR1) also known as TRPV1 or capsaicin receptors167-170. 
This particular class of receptors are usually Ca2+-channels that are expressed in 
neurons and play a role in signaling of noxious stimuli, including heat and 
pH171,172. They are the cellular target of capsaicin, the active component of hot 
peppers, but are also activated by a range of inflammatory mediators. Although, 
the VR1 class proteins are not expected to be present in Xenopus skin cells, it 
cannot be ruled out that 37P11 influences calcium signaling in the cells, leading 
to the observed changes in aggregation behavior. 
To identify 37P11 targets, two important points regarding the compound needed 
to be addressed: a suitable attachment point in the molecule for an affinity linker 
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and an increase in potency of the compound. To achieve both goals I carried out 
a structure-activity relationship (SAR) study for 37P11. First, information from the 
primary screen was briefly analyzed. Among the compounds initially screened, 
only one additional library member belonged to the same template as 37P11, 
and it showed very similar activity to 37P11. Since it structurally resembles 
37P11 closely, not much information could be obtained from this data point. For 
the detailed SAR study the molecule was divided into 4 parts: the pyridine ring, 
the piperazine ring, the urea linkage, and the phenyl ring (Figure 30B). 
Employing a modular tactic, the parts of the molecule were individually varied 
using different substitutions to see changes in activity and guide the design of 
more potent analogs. On either end of the molecule, larger functional groups, 
such as esters, silicon ethers or biotin, were also introduced to test if potential 
linkers for affinity probes would be tolerated. The designed analogs were then 
synthesized, mostly in a two step procedure, including a nucleophilic substitution 
on the pyridine ring followed by the urea-forming reaction of the corresponding 
isocyanate with the piperazine (Figure 30A). Of the more than 40 analogs 
synthesized and tested, none was significantly more potent in the primary assay 
than the parent compound, 37P11. Additionally, introduction of larger functional 
groups led to a loss of activity (Table 2, appendix). Accordingly, only compounds 
with relatively minor changes in molecular structure were among the ones that 
showed comparable activity to the parent compound (Figure 30C). In summary, 
while biologically active analogs of 37P11 could be found in the SAR-study, no 




Figure 30: Analogs of 37P11 in SAR Studies 
(A) General synthesis scheme for 37P11 and its analogs. (B) Overview over the 41 synthesized 
analogs of 37P11. Generally, only one part of the lead structure was changed at a time to the 
functional groups shown. (C) Structures of the 5 analogs that retained comparable activity to the 
parent compound 37P11. Among them is 36B13, another hit in the primary screen from the same 





suitable attachment point for an affinity-based linker became apparent. In light of 
these results, target identification for this interesting compound did not appear 
feasible at this point in time. 
Effects of 37P11 in Other Biological Contexts 
Although target identification studies for 37P11 proved difficult, I was still 
interested in studying its effects in biological contexts other than melanosome 
movement. A closely related process is the bidirectional movement of lysosomes, 
another membranous organelle whose transport within the cell depends on 
dynein, a kinesin, and a myosin158,161. Lysosomes, as principal sites of 
intracellular digestion, are characterized by a low internal pH, allowing them to be 
stained with pH-sensitive fluorescent dye in living cells. Using this approach, I 
imaged and tracked lysosomes in Xenopus melanophores in the absence and 
presence of 37P11, to study the compound‟s effect on their motility. As readout 
the diffusion coefficient was determined (displacement2/time), which is unaffected 
by the directionality of movement. While a high percentage of lysosomes in 
compound treated cells still showed a high diffusion coefficient, indicating active 
microtubule based transport, their number was somewhat reduced as compared 
to untreated cells (Figure 31).  The difference seems to be an increased number 
of lysosomes with no or very slow apparent movement. Without the knowledge of 
the molecular target of 37P11, the interpretation of this data is difficult, but it 
might indicate that 37P11 is able to induce on increase in switching of lysosomes 




Figure 31: 37P11 Affects Movement of Lysosomes in Cells 
Fluorescently labeled lysosomes were tracked in treated (37P11, 50 M) or untreated (DMSO) 
live melanophores. Lysosome motility distribution is shown according to diffusion coefficient. At 
least 41 organelles (from more than 10 cells each) were tracked for each experiment. Error bar 
shows s.d. from two independent experiments. 
 
Chromosomes in vertebrate cells show a regular oscillatory movement during 
mitosis, an intracellular transport process that can be easily observed. The switch 
in direction during the oscillation is usually abrupt, and has been termed 
„directional instability‟173,174. The exact mechanism for chromosome oscillation is 
not well understood, but a tug-of-war like mechanism is suspected to play a role. 
This would involve forces generated by motors as well as forces generated by 
microtubules3,175-177. For the analysis of chromosome oscillation in the presence 




Figure 32: 37P11 Can Affect Chromosome Oscillations in Metaphase Cells 
PTK cells were treated with monastrol (100 M) for 30 min and then 37P11 or DMSO were added 
30 min before imaging using a 40x phase objective. For visualization of the chromosome 
movement 31 frames with a 20s interval were taken. Plotting the intensities along a fixed line 
(distance) over all frames results in a kymographic image. (A) depicts a DMSO treated cell as an 
example of observable oscillations as clearly demonstrated by the zig-zag pattern in the 
corresponding kymographs. (B) One of the  37P11 treated cells (50 M) that shows static 
chromosomes as seen by the straight lines in the kymographs. Regions for kymographic analysis 
are shown as white lines. Scale bars, 10 m. 
 
arrested in mitosis, and then incubated with 37P11. Time-lapse live-cell 
microscopy was used to image chromosomes and evaluate their movement over 
time. The movement of single chromosomes was then visualized using 
kymography (Figure 32A,B). While in the control cases all cells (12/12) showed 
chromosome oscillations, in the case of 37P11 chromosome oscillation was 
observed in only 7/15 cells (Figure 32A,B). This data indicates that 37P11 may 
also have an effect in this biological system, but the potential molecular target 
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remains elusive. It cannot be ruled out, that the observed effect may be an 
indicator of general cytotoxicity of 37P11, given the fact that the cell division 
apparatus is very sensitive to perturbations of various kinds. 
37P11 could be shown to be active in other biological contexts than melanosome 
movement but further studies would be needed to identify its exact role. Without 
fully understanding the role of 37P11 in melanosomes movement, an extension 
into other systems will remain difficult. 
Conclusion 
Identification of a number of small molecules that are active as inhibitors of 
aggregation showed that this screening approach is viable. One of the most 
promising compounds, 37P11, could be characterized as an inhibitor of a 
regulatory pathway, but as in many screens, target identification for the 
compound appeared to be the most difficult step and wasn‟t feasible. Although 
37P11 showed activity in a range of different biological systems, in the absence 
of an identifiable target the compound has only limited value for further biological 
studies. In addition, the potential of off-target activities as suggested by the 
relatively high IC-value and known biological targets that could alter relevant 
calcium levels, are potential drawbacks, too. Therefore, 37P11 was not pursued 
further for biological application. Other identified inhibitors of melanosome 
aggregation from this unbiased library still hold promise for biologically active 
probes of intracellular transport. 
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3.3.3. Overview over Results from the Screen of the DAP Collection 
The primary screen was carried out in triplicate in a high-throughput fashion 
using a subset of the DAP collection described earlier. Of the 53 compounds 
tested in the screen at 10 M, 7 were identified and confirmed as hits. The 
observed hit rate of about 13% of the tested collection is surprisingly high, 
especially as compared to about 1% hit rate observed in the case of the 
“Chemdiv” library. On the other hand, the hit rate is more comparable to the one 
seen with the same compounds in the phenotypic screen for cell division 
phenotypes (41%). The somewhat lower number could be explained by several 
reasons, such as the lower compound concentration used in the case of the 
melanophores (10 M vs. 20 M), a higher sensitivity towards perturbations in 
cell division vs. in melanosome transport in interphase, or the difference in cell 
types used (Xenopus melanophores vs. BS-C-1 cells). Nevertheless, the 
considerably increased hit rate using the DAP-collection supports the assertion 
that it contains a bias towards biological activity. Since this „bias‟ was observed in 
two different biological systems, the idea of screening „privileged scaffolds‟ might 
prove viable on a larger scale. 
Of the 7 hits, one compound strongly affected the interphase microtubule 
skeleton of melanophores and was not considered further. The remaining 6 
compounds were tested in the organelle motility assay to reveal that 2 of them 
are able to stop organelle movement, indicating that they might target the 
involved motor proteins directly. The more potent compound of the two, DAP-29, 
was then selected for further testing of potential targets. Even without knowing 
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the precise molecular targets of the 7 compounds, it is clear that they fall at least 
into two different categories regarding the mode of inhibition of aggregation, 
which supports the idea that structurally related compounds (DAPs) can give the 
same phenotype by targeting different proteins. 
Comparing the hit compounds from the melanophore screen as well as the 
screen for mitotic phenotypes, it is interesting to note that of the 7 compounds 
identified in the melanophore screen, 3 were not identified in the other screen, 2 
scored as having mitotic defects, whereas the remaining 2 scored as effectors of 
the microtubule skeleton. This result illustrates that both screens seem to identify 
a different set of compounds with some overlap present. 
3.3.4. DAP-29 as a Potential Inhibitor of Dynein Mediated Processes 
DAP-29, a 2,4-diaryl diaminopyrimidine, was identified as an inhibitor of 
melanosome aggregation (Figure 33A). In contrast to 37P11, DAP-29 clearly 
belongs to the second class of compounds, which inhibits aggregation in the 
primary assay by stopping organelle movement. Therefore, the potency of DAP-
29 can be easily determined using organelle movement in live cells. From the 
tracking data provided by my collaborator Vladimir Gelfand (Northwestern 
University), I determined the IC50 to be 6 M, which is in agreement with the 
compound being a hit at the screening concentration of 10 M (Figure 33B,C). In 
addition, removal of the compound from cells by replacing the medium (washout) 
led to a full recovery of melanosome movement indicating that the effects of 




Figure 33: DAP-29 Reversibly Inhibits Melanosome Movement with an IC50 of 6 M 
(A) Chemical structure of DAP-29. (B) Dose response curve for melanosome movement in the 
presence of varying concentrations of DAP-29 using mean square displacement (MSD) per time 
(1s intervals) as measure. (C) IC50 was obtained using a logistic curve fit, as shown. (D) 
Melanosomes in cells treated with 20 M DAP-29 showed a full recovery of movement after 
removal of the compound (washout), as compared to the untreated control (MSD per 4s period 
used). At least 14 melanosomes were tracked for each data point. Error bars show s.d. 
 
Potential Protein Targets of DAP-29 
Given the fact that DAP-29 can stop melanosome movement, its relevant protein 
target is expected to be closely associated with the transport process itself. This 
includes the essential motor proteins, namely heterotrimeric kinesin II, 
cytoplasmic dynein, and myosin V, as well as their tracks, microtubules and 
actin.   
As first step, I evaluated the interphase microtubule skeleton of melanophores in 
the presence of the DAP-29 to see any potential effect. After treatment of the 
cells with 20 M compound for 4 hours, a marked change occurred. The cells 
retracted somewhat, and a bundling of interphase microtubules seemed to occur 
(Figure 34A). While this rules out a strong depolymerizing effect of DAP-29 at 
relevant concentrations, it clearly indicates that microtubule architecture is 
affected, either by direct action of the compound on microtubules or by indirect 
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actions through microtubule associated proteins (MAPs). One of the relevant 
MAPs could be cytoplasmic dynein and the associated dynactin, since it has 
been reported that inhibition of their interaction can lead to problems in the 
interphase microtubule skeleton178. Of note, DAP-29 was found to affect 
interphase microtubules in the screen for mitotic phenotypes in BS-C-1 cells, 
corroborating the findings in melanophores. A specific assay to look for increased 
polymerization or depolymerization of purified microtubules in an in vitro setting 
(in the absence of microtubule associated proteins) was not conducted: however, 
it should be noted that no noticeable effects on microtubules themselves were 
observed in the microtubule sliding assays described below. This finding 
indicates that direct effects on microtubules are unlikely to be important at the 
compound concentration used. The treatment period of 4 hours might also be 
less relevant for effects seen in the screen on a 1 hour time frame.  
To analyze whether the actin skeleton as well as the activity of the actin 
dependent motor myosin V are affected, the actin dependent transport in 
melanophores was tested in live cells (carried out by Vladimir Gelfand). This can 
be achieved similarly by organelle tracking as described above, but to separate 
the actin from the microtubule dependent part of melanosome motility, the 
microtubule skeleton was first depolymerized using nocodazole. Tracking of 
organelles in either DAP-29 treated or the untreated case showed very similar 
curves for the mean square displacement over time (Figure 34B). This finding 
indicates that neither actin nor actin-dependent transport by myosin V are 
significantly affected by DAP-29 in cells.  
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This result left inhibition of microtubule-based transport as the most likely 
explanation of the observed effects. To indicate whether DAP-29 can inhibit one 
of the relevant motors for this transport, cytoplasmic dynein or kinesin II, directly, 
microtubule sliding assays can be used. Cytoplasmic dynein could be isolated 
and purified from bovine brain for this experiment, however, kinesin II was not 
accessible. Therefore two other kinesins, conventional kinesin (kinesin I) and a 
member of the kinesin V family, Eg5, were used, which only allowed limited 
conclusions about effects of DAP-29 on the more relevant kinesin II. In all three 
cases, no strong effects of DAP-29 could be observed in the sliding assay at 
concentrations used in the primary screen (10 M, data not shown). Interestingly, 
effects on microtubule sliding were clearly visible at higher concentrations (100 
M) with all three motor proteins (Figure 34C-E). This result may be interpreted 
in several ways. First, DAP-29 does not target cytoplasmic dynein or kinesin II 
directly and the effects seen at higher concentrations are due to off-target effects, 
potentially on tubulin. Second, DAP-29 targets cytoplasmic dynein, but because 
of differences in species of this multi-protein motor complex, this effect is only 
seen at higher concentration in the in vitro assay. Alternatively the higher potency 
in cells could be due to an accumulation effect. Third, the relevant target may be 
kinesin II, and because this protein is unavailable, it cannot be tested 
conclusively. While it is difficult to differentiate between these, and other 
alternative explanations for the observed results in in vitro assays, testing of the 
compound in other biological context may prove useful, especially to find out 





Figure 34: DAP-29 Effects on Microtubules and Several Motor Proteins 
(A) Melanophores were treated for 4 h with either DMSO (control) or 20 M DAP-29, fixed, and 
stained for -tubulin (green) and DNA (blue). Color combined fluorescence images show an 
effect of DAP-29 on the interphase microtubule skeleton that includes bundling and cell retraction. 
(B) Tracking of melanosomes in live cells in the absence of microtubules (nocodazole 
depolymerized) showed no significant differences in the control and DAP-29 treated case (20 
M), demonstrating that myosin V mediated transport is unaffected (data from VG). (C-E) In vitro 
microtubule sliding assays were used to observe effects of DAP-29 on either cytoplasmic dynein, 
Eg5, or conventional kinesin, respectively. Strong effects on dynein motility were only seen at 100 
M DAP-29. At that concentration motility of Eg5, with monastrol as positive control, and 
conventional kinesin were also strongly affected. The sliding assays contained 1 mM ATP as 




DAP-29 in Other Biological Systems 
The following studies, describing the effects of DAP-29 on other intracellular 
transport processes were carried out by collaborators in the laboratory of 
Vladimir Gelfand and therefore will be only briefly discussed here. 
Sperm motility is dependent on active flagellar motion, which in turn is dependent 
on functioning axonemal dynein that slides microtubules against each other in an 
energy (ATP) dependent manner179. In the case of sea urchin the sperm can be 
easily collected and its movement studied. In the presence of 20 M DAP-29 a 
shutdown of movement is observed, indicating that the compound might be 
targeting dynein. Since the flagellar movement does not depend on kinesin, this 
result suggests that among different alternatives dynein might be the more 
relevant target. 
 Similar to the movement of melanosomes, other cargoes are transported 
bidirectionally in the cytoplasm of cells. Among them are peroxisomes, 
organelles that carry out oxidative reactions using molecular oxygen, and 
messenger ribonuclear-protein complexes (mRNPs), that play important roles in 
gene expression164. In the case of peroxisome and mRNPs, their transport 
depends on cytoplasmic dynein and conventional kinesin180,181. Separate 
observation of both cargoes in Drosophila S2 cells, each can be visualized by 
fluorescently tagging specific proteins, in the presence of DAP-29 showed that 




Figure 35: DAP-29 Affects Peroxisome Movement, Another Dynein Dependent Intracellular 
Transport System 
Fluorescently labeled peroxisomes in Drosophila S2 cells were imaged and tracked to observe 
their movement in the presence of DAP-29. The diffusion coefficient was determined as mean 
square displacement per imaging interval (1 second). Actin based transport was disabled by 
addition of cytochalasin. At least 33 particles total from 5 or more cells were tracked for both 




The observation that DAP-29 blocks movement in other microtubule dependent 
transport systems that depend on cytoplasmic dynein, but not on kinesin II, 
suggests the possibility that dynein might be a protein target of this compound. In 
addition, the clear activity of DAP-29 in other biological systems supports the 
idea that compounds identified in the melanophore screen can have general 
applicability to study intracellular transport processes. 
Normal myosin V dependent motility in melanophores already indicated that 
DAP-29 does not act non-specifically on ATP-dependent transport processes, for 
instance by depleting ATP. To test this hypothesis further, actin-dependent 
membrane ruffling in the presence of DAP-29 was examined. No effect on this 
ATP dependent but dynein independent process was observed, indicating that 
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DAP-29 does not act non-specifically on all transport processes (data not 
shown). 
It has become clear that DAP-29 effects dynein dependent processes in several 
in vivo systems, but does not seem to target dynein independent processes. This 
is intriguing, but not compelling, evidence that DAP-29 acts on cytoplasmic 
dynein as relevant target. 
Summary 
Identification of DAP-29 as an inhibitor of melanosome movement, possibly via 
inhibiting cytoplasmic dynein, further validates the screening approach using 
melanophores as model for intracellular transport. In addition, screening of 
compound collections based on a „privileged scaffold‟ such as 
diaminopyrimidines appeared promising in the case of melanophores as well. 
DAP-29 biological activity in a range of dynein dependent processes correlates 
well with this motor protein or a closely related factor being the relevant target. 
Although conclusive evidence of direct targeting of dynein is missing at this point, 
further testing in additional biological systems and crosslinking studies might 
corroborate the finding in the future, and could also help to further address the 
specificity of the compound. 
3.4. Conclusion 
Phenotypic screening for inhibitors of intracellular transport in Xenopus 
melanophores proved successful, as inhibitors such as DAP-29 and 37P11 that 
target different aspects of organelle movement, show. Preliminary studies in 
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other biological systems indicate that these compounds are not active only in 
melanosome transport, but also in a wide array of intracellular transport 
processes. However, problems with target identification and validation need to be 
resolved before compounds from this screen can be fully utilized as biologically 
active probes. 
Two different compound collections have been used in the screen: the unbiased 
library, and the collection based on a „privileged scaffold‟. Both collections 
yielded interesting, biologically active compounds, indicating that both 
approaches can be successful. However, the use of a „privileged scaffold‟ may 





Phenotypic screens were used to identify small molecule probes of cell division 
and intracellular transport.  In the process of this work, compounds based on a 
„privileged scaffold‟ proved to be a viable starting point for small molecule 
discovery, implying that a broader use of „privileged scaffolds‟ may lead to more 
effective screens. The work also reconfirms that, while target identification and 
compound specificity still remain major challenges in the field of small molecules, 
bioactive probes from phenotypic screens can provide powerful and valuable 
insights into biological processes. The further development of phenotypic 
screens and the continued exploration of chemical space should generate many 






4. Material and Methods 
4.1. Phenotypic Cell-based Screen and Plk inhibitors 
4.1.1. Chemical Synthesis and Characterization of DAP-library Members 
Unless otherwise noted, materials were obtained from commercial suppliers and 
were used without further purification. Anhydrous grade solvents were purchased 
from Aldrich and used directly. Solvents were generally removed by distillation 
using a Büchi rotary evaporator attached to a vacuum pump. Obtained products 
were dried under high vacuum. Analytical thin-layer chromatography was 
performed on pre-coated silica plates (Whatman F254, 0.25 mm thickness); 
compounds were visualized by UV-light or by staining using anisaldehyde spray, 
potassium permanganate solution, or ammonium molybdate/ceric sulfate 
solution. NMR-spectra were recorded on a Bruker DPX 400 (400 MHz for 1H) 
spectrometer. Chemical shifts () are quoted in ppm and are referenced to the 
respective solvent (CDCl4 =7.24, DMSO-d6 =2.50). LC/MS data was obtained 
using a Waters LC-MS ZQ 2795 spectrometer equipped with a Waters symmetry 
C18 2.1x50 mm column at a flow rate of 0.2 mL/min. 
The members of the library were synthesized by sequential nucleophilic 
substitution of dichloropyrimidines. 3-Nitro-2,4-dichloropyrimidine (NDCP) and 








































Typical procedure (adapted from78,83) 
For DCP-derivatives: 
Step I: To a solution of the DCP (20 mmol, 3 g, 1 eq.) in 20 mL 1-butanol was 
added Hünig‟s base (24 mmol, 4.2 mL, 1.2 eq.) and amine/aniline (20 mmol, 1 
eq.). The resulting mixture was heated at reflux for 24 h.  Then the reaction 
mixture was cooled, evaporated and the residue crystallized from ethyl acetate to 
afford the monosubstituted chloropyrimidine derivative. 
Step II: To a solution of the monosubstituted chloropyrimidine (0.2 mmol) in 2-
propanol (4 mL) was added the amine/aniline (0.2 mmol) and ethereal HCl (0.2 
mL) and the mixture heated to reflux for 24 h.  After cooling the mixture to room 
temperature, the precipitate was filtered, washed with ether and dried in vacuo.  
In cases were no precipitate formed upon cooling, cold ether was added to the 





For NDCP derivatives: 
Step I: To a solution of NDCP (2.6 mmol, 0.5 g, 1 eq.) in THF (4 mL) was added 
Hünig‟s base (3.1 mmol, 0.54 mL, 1.2 eq) and cooled to -78 oC.  A solution of the 
amine/aniline (2.6 mmol, 1.0 equiv) in 1 mL THF was then added dropwise.  At 
the end of 2 hours, the mixture was allowed to warm to room temperature and 
poured into water. The obtained precipitate was filtered, washed with water and 
dried. In cases where no solid was formed, the product was extracted using 
chloroform, followed by removal of the solvent in vacuo and drying. 
Step II: The resulting monosubstitued pyrimidine derivative (0.2 mmol, 1 eq.) was 
dissolved in iso-propanol (4 mL) and Hünig‟s base (0.2 mmol, 35 L, 1 eq.) was 
added.  Then the corresponding amine/aniline (0.2 mmol, 1 eq.) was added and 
the mixture was heated to reflux.  After 24 hours, the mixture was cooled to room 
temperature and diluted with cold ether to induce precipitation. The product was 
isolated by filtration, washed with ether and dried in vacuo. 
 
All library members were analyzed by LC/MS. 1H-NMR data for selected 










1H-NMR (400 MHz, DMSO-d6):  10.66 (bs, 1H), 10.25 (bs, 1H), 9.98 (s, 1H), 
7.89 (d, J = 6.9 Hz, 1H), 7.54 (bs, 4H), 7.40 (s, 4H), 6.39 (d, J = 7.1 Hz, 1H), 2.04 









1H-NMR (400 MHz, DMSO-d6):  10.27 (bs, 1H), 10.01 (s, 1H), 9.07 (d, J = 7.7 
Hz, 2H), 8.92 (s, 2H), 8.34 (d, J = 5.9 Hz, 1H), 7.65 (d, J = 8.8 Hz, 2H), 7.55 (m, 














1H-NMR (400 MHz, DMSO-d6):  10.62 (bs, 1H), 8.69 (bs, 1H), 8.23 (bs, 1H), 
7.83 (d, J = 7.1 Hz, 1H), 7.43-7.23 (m, 2H), 7.09-6.91 (m, 4H), 6.28 (d, J = 6.1 









1H-NMR (400 MHz, DMSO-d6):  10.63 (bs, 1H), 10.29 (bs, 1H), 7.88 (d, 7.0 Hz), 
7.4-7.14 (m, 4H), 6.97-6.89 (m, 2H), 6.36 (d, J = 7.0 Hz, 1H), 6.04 (s, 2H), 2.87-







DAP-49. 2-[benzothiazol-6-ylamino]-4-[indan-5-ylamino]-pyrimidine hydrochloride 
1H-NMR (400 MHz, DMSO-d6):  10.88 (s, 1H), 10.83 (s, 1H), 9.36 (s, 1H), 8.39 
(bs, 1H), 8.09 (d, J = 8.7 Hz, 1H), 8.00-7.98 (m, 1H), 7.57 (d, J = 8.7 Hz, 1H), 
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7.44 (s, 1H), 7.27-7.19 (m, 2H), 6.49 (d, J = 6.7 Hz, 1H), 2.86 (t, J = 7.3 Hz, 2H), 








DAP-59.  2-[2-(benzo[1,3]dioxol-5-ylamino)]-4-[2-benzoyl phenylamino]-5-nitro-
pyrimidine 
1H-NMR (400 MHz, DMSO-d6):  11.22 (s, 1H), 10.35 (bs, 1H), 9.00 (s, 1H), 8.09 
(m, 1H), 7.68-7.38 (m, 8H), 7.25 (s, 1H), 7.00-6.98 (m, 1H), 6.80-6.78 (m, 1H), 












1H-NMR (400 MHz, DMSO-d6):  11.25 (bs, 1H), 10.28 (bs, 1H), 8.99 (s, 1H), 
8.13-8.11 (m, 1H), 7.72-7.37 (m, 12H), 6.88-6.81 (m, 2H), 3.24-3.13 (m, 8H), 








DAP-81. 2-[4-acetamidyl phenylamino]-4-[2-benzoyl phenylamino]-5-
nitropyrimidine hydrochloride (previously reported in83)  
1H-NMR (400 MHz, DMSO-d6):  11.15 (bs, 1H), 10.38 (bs, 1H), 9.87 (s, 1H), 












1H-NMR (400 MHz, DMSO-d6):  10.15 (bs, 1H), 8.93 (s, 1H), 8.86-8.84 (m, 1H), 
7.65-7.63 (m, 2H), 6.90 (d, J = 9.0 Hz, 2H), 3.57-3.52 (m, 2H), 3.27-3.10 (m, 8H), 
2.24 (s, 3H), 1.64-1.59 (m, 2H), 1.40-1.33 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H); 
LC/MS (m/z) 387 (M+1). 
 
The „frequent hitter‟182,183 was synthesized as previously described. 
 
4.1.2. Library Analysis for PCA 
For chemical descriptor space analysis, OMEGA (Optimized Molecular Ensemble 
Generation Application, Openeye Scientific) was used to generate 3-dimensional 
conformers and output poses of each compound. They were then processed by 
VIDA (Openeye Scientific) to calculate the following 10 descriptors:  partition 
coefficient (LogP), polar surface area (PSA), molecular weight, number of atoms, 
number of bonds, formal charge, number of carbons, number of hydrogens, 
number of rigid bonds, and number of rotatable bonds. Principal component 
analysis of the parameter set for all compounds was performed using R (r-
project.org) to calculate the three components that spanned the greatest 




4.1.3. Cell Culture, Antibodies, siRNA and Chemical inhibitors 
BS-C-1 cells (monkey epithelial kidney) and U20S cells (human osteosarcoma) 
were cultured in Dulbecco‟s modified Eagle‟s medium (DMEM; Invitrogen, 
Carlsbad, CA) with 10% fetal bovine serum (Sigma, St Louis, MO) and penicillin–
streptomcyin (100 U/ml and 100 µg/ml, respectively; Invitrogen), at 37°C in a 
humidified atmosphere with 5% CO2. PTK and PTKT cells (rat kangaroo kidney) 
were maintained similarly using Ham‟s F12 medium (Invitrogen, Carlsbad, CA) 
instead of DMEM. 
For fixed cell experiments, cells were transferred onto 10 mm round no. 1.5 glass 
coverslips and grown in 100 mm Petri dishes. For live-cell recordings, cells were 
transferred onto square 22 mm no.1.5 coverslips and grown in 100 mm Petri 
dishes. 
Antibodies used for immunofluorescence microscopy were against -tubulin 
([mouse, FITC-DM1, Sigma, 1 g/mL] or [rat, MCA77g, Serotec, 0.5 g/mL]), -
tubulin (mouse, GTU-88, Sigma,1:5000), Cdc25C (mouse, DCS193, Calbiochem, 
1 g/mL), phospho-Cdc25C (Ser 198, rabbit, Cell Signaling, 1:100), human 
CREST antiserum (a gift from W. Brinkley, Baylor College of Medicine, Houston, 
TX) and phospho-histone H3 (Ser 10, rabbit, Upstate Biotechnology, 1 g/mL). 
The appropriate secondary antibodies were purchased from Jackson 
ImmunoResearch Laboratories. DNA was labeled with Hoechst 33342 (Sigma, 1 
g/mL). Antibodies used for Western blotting were against Polo-like kinase 1 
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(mouse, sc17783, Santa Cruz Biotechnology, 0.4 g/mL) and p50 (rabbit, 
D74620, Transduction Laboratories, 0.25 g/mL). 
The siRNA experiments in non-synchronized U20S cells were performed using 
Oligofectamine in Opti-MEM I (Invitrogen) medium following the manufacturer‟s 
instructions (Invitrogen). The siRNAi duplex targeting human Plk1 was described 
previously94 and water was used for mock transfection (control). 45 hours after 
transfection, cells were either stained for immunofluorescence or cells from a 
mitotic shake-off (nocodazole-treated, 1 g/mL, 16 hours) were lysed for Western 
blot analysis. 
BTO-1110,184 and ON01910185 were synthesized as previously described.  
Immunofluorescence 
BS-C-1 cells in the screen were treated for 4h with the respective compounds 
and then fixed at 37°C with 4% formaldehyde in 100 mM PIPES at pH 6.8, 10 
mM EGTA, 1 mM magnesium chloride and 0.2% Triton X-100 for 10 minutes. 
After fixation, cells were blocked in TBS with 0.1% Triton X-100 and 2% bovine 
serum albumin (BSA), and stained for -tubulin in the same medium. DNA 
staining was carried out subsequently in TBS with 0.1% Triton X-100. Images for 
presentation were acquired as Z-stacks with 0.2-µm spacing using a 100x, 1.35 
NA objective on a DeltaVision Image Restoration Microscope (Applied Precision 
Instruments, Issaquah, WA and Olympus, Melville, NY), and processed by 
iterative constrained deconvolution (SoftWoRx, Applied Precision Instruments). 
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Maximal intensity projections of the entire Z-stack are shown. For visualization of 
-tubulin the cells were fixed for 10 minutes in methanol at -20°C. 
U20S cells, either from the RNAi knock-down experiment or after 4-hour-
treatment with the chemical inhibitor, were fixed for 10 minutes in methanol at -
20°C and then blocked and stained as described above. Images for presentation 
were acquired as described above using the Deltavision Image Restoration 
Microscope. 
Quantitative Aspects of Immunofluorescence 
For quantitation of phospho-H3 staining PTK cells were treated for 4 hours with 
100 M monastrol. Then the cells were incubated for 1 hour with test compound, 
20 M MG132, and monastrol. After fixation with formaldehyde and staining, 
images were acquired on a Carl Zeiss Axioplan 2 microscope with a 40x 0.75 NA 
objective. Phospho-H3 immunofluorescence intensity was measured using 
MetaMorph software (Universal Imaging, Downington, PA) and normalized to the 
control (n = 3, ≥ 20 cells for each data point). For each mitotic cell, Hoechst 
fluorescence was used to define the chromosome region, and total phospho-H3 
immunofluorescence was measured in that region using the integrated intensity 
function. Background fluorescence, estimated from intensity measurements in 
regions with no DNA, was subtracted. 
For quantitation of Cdc25C and phospho-Cdc25C staining PTK cells were 
treated for 1 hour with the respective compounds, pre-extracted with MTSBx (4 
M glycerol, 100 mM K-PIPES, 1 mM EGTA, 5 mM MgCl2, 0.5% triton X-100, pH 
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= 6.9) and fixed with methanol at -20°C for 10 minutes. The subsequent blocking 
was carried out as described above. After staining for Cdc25C, phospho-
Cdc25C, and DNA, images were acquired on a Carl Zeiss Axioplan 2 
microscope, with either a 63x 1.4 NA objective (for presentation) or a 40x 0.75 
NA objective (for quantification). Phospho-Cdc25C immunofluorescence intensity 
on centrosomes was quantified in mitotic cells using MetaMorph software 
(Universal Imaging, Downington, PA) and normalized to the Cdc25C intensity on 
the same centrosome using previously described methods (n = 3, ≥ 20 cells for 
each data point)186. The intensity ratio for the control (DMSO) was set to 1. 
For quantitation of inter-kinetochore distances, PTKT cells were treated for 1 
hour with MG132 (20 M) and then for 45 minutes with the respective compound 
in the continuing presence of MG132. Cells were fixed for 10 minutes in 
methanol at -20°C and then blocked and stained as described above. Image 
planes covering the cell volumes were acquired using the DeltaVision Image 
Restoration Microscope. The distance between the centers of CREST antigen 
intensity of a kinetochore pair, was directly measured in three dimensions using 
SoftWoRx (Applied Precision Instruments). Only pairs of kinetochores for which 
attachment to opposite poles could be clearly detected were included (except 
with nocodazole) in the quantitation ( ≥ 67 kinetochore pairs total from ≥ 9 cells 




4.1.4. Screening Procedure 
For the screen, BS-C-1 cells were plated in a 384-well format using a Matrix 
Technologies wellmate multidropper 48 hours before the experiment. 
Compounds were added by pin transfer to solution plates and then transferred to 
the almost confluent cells using the MiniTrak V liquid handling robot (Perkin 
Elmer) to give a final concentration of 20 M, and 10 or 5 M as required. After a 
4-hour-incubation fixation and staining (see above) were performed using a wand 
aspirator (VP scientific) and a multichannel pipettor (Matrix technologies) for 
liquid handling. One image per well (blue channel for DNA and green channel for 
-tubulin) was acquired using the Discovery-1 (Molecular Devices) automated 
microscopy system with a 10x Nikon objective. Analysis of the images by visual 
inspection led to the identification of active compounds (detailed description of 
criteria in Figure 37).  
 
4.1.5. Kinase Assay 
Polo-like kinase 1 activity was assayed in kinase buffer (50 mM Tris [pH 7.6], 10 
mM MgCl2, 5 mM DTT, 2 mM EGTA, 0.5 mM Na3VO4, 20 mM NaF, 20 mM -
glycerophosphate). 3 μg casein, 100 ng of recombinant Xenopus Polo-like kinase 
1 (expressed and purified similarly as described before187), and the appropriate 
amount of compound in DMSO (5% final) were added to half the reaction volume 
(10 L), and allowed to incubate for 30 minutes on ice. Then 10 L of kinase 
buffer containing cold ATP (50 M final) and -32P-ATP (2.5 Ci final) was added. 
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Reactions were mixed, incubated for 15 minutes at 30°C, stopped by the addition 
of Laemmli sample buffer. Proteins were resolved by SDS-PAGE (12.5%). Gels 
were dried, and exposed to a phosphorimager screen. Gel bands were quantified 
with Image Gauge software (Fujifilm). 
 
4.1.6 Live cell imaging 
Cells on 22x22 mm coverslips were mounted in a Rose chamber for imaging 
using L-15 medium without phenol red supplemented with FBS, antibiotics (see 
above), and 20 M MG132 (if indicated). Chemical inhibitors were introduced 
either during the initial mounting or added later by medium exchange. If MG132 
was used, cells were pre-incubated with it in 35 mm dishes for 30 minutes to 1 
hour. For reversibility tests inhibitor containing media were exchanged with 
media containing the appropriate amount of carrier (DMSO) instead of 
compound. 
Confocal GFP fluorescence time-lapse sequences were acquired on a Carl Zeiss 
Axiovert 200M microscope equipped with a z-motor and a 100x 1.4 NA objective. 
Experiments were performed at 37°C using an air curtain (Nevtek, Burnsville, 
VA). Z-stacks (seven sections separated by 1.0 m) of GFP fluorescence were 
taken with an Orca ER cooled CCD camera (Hamamatsu, Hamamatsu City, 
Japan) coupled to a Yokogawa spinning disk confocal QLC100 unit. Illumination 
was achieved with an argon laser (Solamere, Salt Lake City, UT) at 488 nm. A 
single DIC image was taken immediately after each GFP stack. MetaMorph 
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software (Universal Imaging) was used for acquisition and analysis. Maximal 
intensity projections of GFP-tubulin z-stacks and single DIC images are shown 
for selected timepoints. A 2x2 lowpass filter was applied to all DIC images for 
presentation. Kymographic analysis was carried out using the kymograph tool of 
MetaMorph software (Universal Imaging, Downington, PA). Phase-contrast 
microscopy was carried out under the same live-imaging conditions using a 40x 
1.3 NA phase objective. 
4.2. Intracellular Transport Screen 
4.2.1. Cell Culture and Cell-based Assays 
Cell Culture of Melanophores 
Xenopus melanophores148 were cultured in 0.7X L-15 medium (Gibco/Invitrogen) 
supplemented with 4% fetal bovine serum (Sigma, St Louis, MO), penicillin–
streptomcyin (100 U/ml and 100 µg/ml respectively; Invitrogen), 5 g/mL insulin, 
and 0.29 mg/mL glutamate at 25°C in a humidified atmosphere in the dark. 
Serum free medium (SFM) has the same composition without containing serum. 
For cell freezing and to reduce the number of pigments to allow easier tracking or 
imaging the cells can be maintained in 1 mM phenylthiourea (PTU) which inhibits 
pigment biosynthesis. To induce dispersion melanocyte-stimulating hormone 
(MSH, M-4135 Sigma, 100 nM active concentration) was used, to induce 
dispersion melatonin (10 or 20 nM active concentration) was used. 
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Immunofluorescence in Melanophores 
Staining for tubulin and DNA was carried out as described for BS-C-1 cells in 
section 4.1.3. using PTU-treated melanophores.  
PKA-inhibitor assay 
Melanophores were plated on 25x25 mm square, poly-lysine coated coverslips 
and transfected 1 day later either with GFP-pNP210 or GFP-pNP211, the active 
and inactive form of a PKA-inhibiting peptide, respectively, using FUGENE-
transfection reagent (Roche diagnostics) according to manufacturer‟s 
guidelines165. Two or three days after transfection, the growth medium was 
exchanged with SFM, incubated for 1 hour, and then the respective compound 
was added in SFM. After 1 hour of incubation with compound, the cells were 
fixed with 3.7% formaldehyde in PBS, and mounted for imaging. The aggregation 
state for GFP-expressing cells was then determined by optical inspection for 
quantitation. 
Lysosome Imaging and Tracking in Melanophores 
PTU-treated melanophores were plated on 25x25 mm square, poly-lysine coated 
coverslips one or two days before the experiment. After washing twice with SFM 
and incubation for 1 hour in SFM, the respective compound was added (0.1% 
DMSO final) in SFM. After 25 min incubation a solution containing compound and 
Lysotracker Red DND 99 (100 nM final, Invitrogen) was added, followed by 
additional 5 min incubation. Then the cells were washed five times with SFM, 
mounted and sealed. Imaging was carried out on a Nikon Eclipse U2000 
microscope with a plan-APO 60 1.4 NA objective. A 100W halogen light source 
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was used for epifluorescence to minimize phototoxicity. 100 images per field 
were captured every 0.2 s with a 0.1 s exposure time using an Orca-II-ER cooled 
charge-coupled device camera (Hamamatsu Photonics, Japan). Tracking was 
carried out by customized software (Ontash & Ermac, River Edge, NJ), and the 
obtained data was binned according to the diffusion coefficient. 
Melanosome Tracking in Melanophores 
Imaging and tracking was carried out in the Gelfand laboratory as previously 
described188. For the studies of melanosome movement in the absence of 
microtubules, nocodazole was added as depolymerization agent. 
Chromosome Oscillation in PTK-cells 
PTK cells were maintained and plated on coverslips as described for PTKT 
cells in section 4.1.3. After incubation with 100 M monastrol for 30 minutes, the 
compound was added (either 60 M 37P11 or DMSO as carrier) and incubation 
was continued for 30 more minutes. Next, the coverslips were mounted in a Rose 
chamber, monopolar mitotic cells were located and then imaged for 10 minutes in 
20 second intervals using a Ph3 40x Plan-NEOFLUAR 1.30 objective on a Carl 
Zeiss Axiovert 200M microscope under phase contrast conditions. 
   
4.2.2. Screening Procedure 
The cells (Xenopus laevis melanophores)148 were plated 2 days before the 
experiment in a 384-well format (~100000 cells per well) using Corning Costar 
black walled, clear bottom plates. A Matrix Technologies wellmate multidropper 
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was used for liquid handling. For the experiment the cells were initially washed 
twice with 50 l of serum free medium (SFM). After incubation with SFM for 45 
minutes at room temperature in the dark, the cells were incubated with MSH (100 
nM) in SFM for 1 hour to achieve full dispersion.  The cells were then washed 
thrice with SFM to remove MSH and the compound of interest (at 20 M for 
Chemdiv or 10 M for DAPs) in SFM was added. Preparation of compound and 
hormone stock solutions was carried out by pin transfer using the MiniTrak V 
liquid handling robot (Perkin Elmer). After 30 min incubation, melatonin (20 nM 
final) was added to each well to induce aggregation.  This mixture was allowed to 
incubate for 1 hour at room temperature in the dark, then the cells were fixed with 
3.7% formaldehyde in phosphate buffered saline (PBS) for 45 minutes at which 
point the media was exchanged for PBS and each plate was stored in the dark at 
4oC, ready for imaging. 
Image acquisition was performed using the Discovery-1 automated imaging 
system.  The wells were usually imaged 5 times each at 20x using this system 
with a 5 ms transmitted light exposure, 2x2 binning, with an image spread that 
covered each well entirely.  The images were analyzed using Metamorph 
software (Universal Imaging, Downington, PA) by thresholding to define the 
pigment occupied areas, and then dividing the number of small objects by the 
number of large objects to determine the dispersion index (DI). Definition of small 
and large objects used pixel area as well as shape factor. Individual cut-offs per 
plate for the DI were determined according to internal controls (nocodazole, 
MSH-treated, untreated/DMSO). The screens were carried out in triplicate. 
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4.2.3. Chemical Synthesis and Characterization of 37P11 analogs 
Chemical synthesis procedures were carried out as described in section 4.1.1. 
Synthesis of 37P11 analogs were generally carried out as previously 
described167 in a two-step procedure, a nucleophilic substitution on a 
chloropyridine by a piperazine followed by the reaction of the free amine of the 
piperazine derivative  with the appropriate isocyanate to yield the urea linked final 
product. 







A N,N-dimethylformamide (30 mL) solution of 1.82 g (10 mmol) of 2-chloro-3-
trifluoromethylpyridine and 0.86 g (10 mmol) of piperazine was stirred for 10 
minutes at room temperature. Then 4.15 g (30 mmol) of anhydrous potassium 
carbonate were added and the resulting suspension was stirred for 1.5 hours at 
140 oC. After cooling, 100 mL of water were added and the mixture was 
extracted 3 times using 65 mL ethyl acetate, each. The combined organic layers 
were then washed two times with 50 mL brine, dried over sodium sulfate and 
concentrated in vacuo to give a light orange oil. The crude was purified by 
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column chromatography on 60 g silica gel using a 95:5 chloroform:methanol 
solvent system to give 1.18 g (5.1 mmol, 51%) of a yellowish oil. 
1H-NMR (400 MHz, CDCl3):  8.41 (d, J = 4.7 Hz, 1H), 7.83 (dd, J1 = 1.5 Hz, J2 = 
7.8 Hz 1H), 6.95 (dd, J1 = 4.8 Hz, J2 = 7.7 Hz, 1H), 3.26-3.23 (m, 4H), 3.01-2.99 









37P11, 4-(3-Trifluoromethylpyridin-2-yl)-piperazine-1-carboxylic acid (3,4-
dichlorophenyl)-amide: 
A toluene solution (1 mL) of 94 mg (0.5 mmol) of 3,4-dichlorophenyl isocyanate 
dissolved was added dropwise over 5 min to 116 mg (0.5 mmol) of 1-(3-
trifluoromethyl-pyridin-2-yl)-piperazine (from step 1) in 1 mL of toluene. A white 
precipitate started to form almost immediately and the reaction mixture was 
stirred for 14 hours at room temperature. The solvent was then removed in vacuo 
to give a white solid. Purification of the crude by column chromatography on 60 g 
of silica gel using chloroform as solvent yielded 161 mg (0.385 mmol, 77%) of a 
white solid as final product. 
1H-NMR (400 MHz, CDCl3):  8.44 (d, J = 3.7 Hz, 1H), 7.88 (d, J = 7.6 Hz, 1H), 
7.55-7.54 (m, 1H), 7.29 (d, J = 8.7 Hz, 1H), 7.18 (d, J = 8.7 Hz, 1H), 7.06-7.02 
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(m, 1H), 6.60 (bs, 1H), 3.62-3.60 (m, 4H), 3.31-3.29 (m, 4H); 13C-NMR (100 MHz, 
CDCl3):  159.4, 154.5, 151.2, 138.5, 137.2, 137.2, 132.5, 130.3, 126.2, 121.6, 
119.2, 117.8, 117.4,  50.4, 44.1; LC/MS (m/z) 419 (M+1). 
The following analogs have similar potency as 37P11 (see Table 2) and their 








UP-II-95, 4-(3-Trifluoromethylpyridin-2-yl)-piperazine-1-carboxylic acid 3,4-
dichlorophenyl ester 
The compound was prepared from the piperazine derivative (step 1) by treatment 
with triphosgene followed by 3,4-dichlorophenol to yield the carbamate linkage. 
1H-NMR (400 MHz, CDCl3):  8.46 (bs, 1H), 7.89 (d, J = 7.1 Hz, 1H), 7.40 (d, J = 
8.7 Hz, 1H), 7.28 (bs, 1H), 7.07-6.99 (m, 2H), 3.77-3.69 (m, 4H), 3.29 (bs, 4H); 
13C-NMR (100 MHz, CDCl3):  159.7, 152.9, 151.2, 150.0, 137.2, 137.2, 132.7, 











The compound was prepared from the piperazine derivative (step 1) by treatment 
with the corresponding acid chloride to yield the amide linkage. 
1H-NMR (400 MHz, CDCl3):  8.42 (bs, 1H), 7.87 (d, J = 6.8 Hz, 1H), 7.39-7.35 
(m, 2H), 7.10-7.04 (m, 2H), 3.76-3.69 (m, 4H), 3.58 (bs, 2H), 3.21-3.16 (m, 4H); 








UP-II-132, 2-Methyl-4-(3-trifluoromethylpyridin-2-yl)-piperazine-1-carboxylic acid 
(3,4-dichloro-phenyl)-amide 
The compound was prepared as described in the general procedure using 1-
methylpiperazine. 
1H-NMR (400 MHz, CDCl3):  8.45 (d, J = 3.6 Hz, 1H), 7.89 (dd, J1 = 1.6 Hz, J2 = 
7.8 Hz, 1H), 7.55 (d, J = 2.5 Hz, 1H), 7.26 (d, J = 8.8 Hz, 1H), 7.19 (dd, J1 = 2.5 
Hz, J2 = 8.8 Hz, 1H), 7.06 (dd, J1 = 4.8 Hz, J2 = 7.8 Hz, 1H), 6.80 (s, 1H), 4.34-
4.32 (m, 1H), 3.88-3.85 (m, 1H), 3.49-3.34 (m, 3H), 3.20 (dd, J1 = 3.6 Hz, J2 = 
12.4 Hz, 1H), 3.02-2.96 (m, 1H), 1.34 (d, J = 6.7 Hz, 3H); 13C-NMR (100 MHz, 
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CDCl3):  160.3, 154.4, 151.2, 138.7, 137.1, 137.1, 132.4, 130.1, 126.1, 121.8, 









37B13, 4-(3-Chloro-5-trifluoromethylpyridin-2-yl)-piperazine-1-carboxylic acid (3-
chloro-phenyl)-amide 
The compound was prepared analogously to 37P11. 
1H-NMR (400 MHz, CDCl3):  8.39 (s, 1H), 7.78 (s, 1H), 7.43 (s, 1H), 7.18-7.15 
(m, 2H), 6.99-6.98 (m, 1H), 6.72 (bs, 1H), 3.63-3.61 (m, 4H), 3.52-3.50 (m, 4H); 










UP-II-139, 4-(3-Chloro-5-trifluoromethylpyridin-2-yl)-piperazine-1-carboxylic acid 
(3,4-dichlorophenyl)-amide 
The compound was prepared analogously to 37P11. 
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1H-NMR (400 MHz, CDCl3):  8.39 (d, J = 1.1 Hz, 1H), 7.79 (d, J = 2.0 Hz, 1H), 
7.59 (d, J = 2.5 Hz, 1H), 7.32 (d, J = 8.7 Hz), 7.18 (dd, J1 = 2.5 Hz, J2 = 8.7 Hz, 
1H), 6.42 (s, 1H), 3.66-3.63 (m, 4H), 3.55-3.53 (m, 4H); LC/MS (m/z) 453 (M+1). 
4.2.4. Motility Assays 
Motility assays were carried out as previously described189, briefly: 
The motor protein in BRB80 (80 mM Pipes, 1mM MgCl2. 1 mM EGTA, pH=6.8 
with KOH, ~7 L) was allowed to bind onto a glass coverslip in a flow chamber. 
After blocking with 0.5 mg/mL of casein in BRB80 for several minutes (20 L), 
fluorescently marked microtubules (X-rhodamine) obtained from GMPCPP seeds 
were added to bind to the motor protein (~10 L). Next motility buffer (BRB80, 
1mM MgCl2, 1 mM ATP, oxidation mix [glucose oxidase, catalase, glucose and -
mercaptoethanol]) containing the compound of interest in DMSO (usually 1% 
total) was added and the movement of microtubule was observed by time-lapse 
microscopy. To calculate sliding velocities, 10 or more microtubules were 
randomly chosen and the distance traveled during the timelapse was measured. 
The following motor proteins/constructs were used in the assay: Eg5 full length at 
0.18 mg/mL189, human conventional kinesin K560 at 0.09 mg/mL190, and 








Figure 36: Composition of the Diaminopyrimidine Library. 
(A-C) Core structure and substituents. Each substituent at R2 and R3 is coded with a letter. 
Number of compounds in the collection with the respective substituents is shown. (D) Chemical 































































































































































































































6 / 3 Spindle/ 
Chromosome 
/ 
For analysis of the primary screen (done in triplicate at 20 M compound concentration) fields of 
cells were analyzed by visual inspection of 10x images. Phenotypes were then assigned 
according to following categories: 1 – strong effects on interphase microtubules, 2 – greatly 
reduced mitotic index, 3 – monopolar mitotic spindles, 4 – spindles with aberrant poles/extra 
poles, 5 – abnormal spindles (other than 3 or 4), 6 – chromosome alignment defects in control-
like spindles, 7 – increased number of cells in anaphase/cytokinesis, 8 – greatly increased mitotic 
index, 9 – visible compound aggregates. If a compound scored at least 2 out of 3 times in one 
category (categories 3-6 were considered as one category for this purpose referred to as 
spindle/chromosome alignment defects) the compound was considered a respective hit. Shown in 
the table are all compound that scored as hit in the screen and do not fall in category 1 or 9. 
Detailed analysis of these hit compounds revealed a range of mitotic phenotypes. A more 










Figure 37: Mitotic Phenotypes Induced by a Subset of DAPs 
A subset of compounds from the screen (Figure 10) was analyzed by high resolution microscopy 
(63x magnification) to characterize mitotic defects. The images show the predominant 
phenotypes for each DAP at 3 (or more) concentrations. The observed divergence in phenotypes 
over the titration indicated differences in the mode of action of the compounds. (A) DAP-62, DAP-
81: Monopolar spindles were observed at 20 M. At lower compound concentrations, spindle 
structures observed had a sphere-like organization. (B) DAP-49: In addition to monopolar 
spindles, cells were observed that had two separated astral microtubule arrays without a well-
defined overlap zone (20 M). At lower concentrations these astral microtubules diminished and 
normal spindles were observed. Quantitation of the phenotypes for this compound is shown in  
Figure 12C. (C) DAP-83: While monopolar spindles were observed at 20 M, spindle pole 
defects, including unfocused poles and additional spindle poles, were also predominant. (D) DAP-
34, DAP-59: Chromosome-alignment defects predominated, with only minor, if any, spindle 
perturbations. (E) DAP-35: The bipolar spindles observed had pole-to-pole distances that were 
less than that observed in untreated dividing cells (40% shorter, n = 13). (F) Normal bipolar 






Figure 38: Additional Images for Comparing Plk1-knock-down and Treatment with 
Chemical Inhibitors 
(A,B) U20S cells were either mock-transfected , or transfected with RNA-oligos against Plk1 as 
previously described
94
. After ~45 hours cells were fixed and processed for immunofluorescence. 
(C-E) After treatment of U20S cells for 4 hours with carrier (DMSO), 25 M DAP-81 or 50 M 
BTO-1 the cells were processed as in (A,B). Overlays show DNA (blue), -tubulin (green) and -
tubulin (red). The distribution of -tubulin is shown separately. As compared to images shown in 
Figure 17A-E, with cells undergoing the same treatment condition, the RNAi-experiment as well 
as treatment with chemical inhibitors can lead to centrosomes that are close together, compared 
to untreated cells. The images show maximum intensity projections of deconvolved image-series 




Table 2: Overview of Activity of Synthesized Analogs of 37P11 
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